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THE GARDEN STATE JUST GOT GREENER: NEW JERSEY IS
THE FOURTEENTH STATE IN THE NATION TO LEGALIZE
MEDICAL MARIJUANA

Melissa Brown∗

I.

INTRODUCTION

On January 11, 2010, both houses of the New Jersey Legislature
passed the New Jersey Compassionate Use Medical Marijuana Act
1
(the NJCMA or the “Act”), making it the fourteenth state in the na2
tion to decriminalize the medical use of marijuana under state law.
∗

J.D., 2010, Seton Hall University School of Law; B.S., 2004, S.I. Newhouse
School of Public Communications, Syracuse University. I would like to thank Dean
Kathleen Boozang, Seton Hall University School of Law, for her assistance in preparing this Comment. I would also like to thank my husband, parents, and in-laws for
supporting me through this endeavor.
1
Bills,
NEW
JERSEY
STATE
LEGISLATURE,
http://www.njleg.state.nj.us/bills/bills0001.asp (click “Bills 2008-2009”; then select
“Search by Bill Number”; then search for “S119”) (last visited Mar. 27, 2011). On
January 8, 2008, members of both houses of the New Jersey legislature introduced
bills intended to legalize the medical use of marijuana via enactment of the NJCMA.
Id. The bills are General Assembly Bill 804 (A804 or “the Assembly bill”) and Senate
Bill 119 (S119 or “the Senate bill”). Id. On December 15, 2008, S119 was reported
out of the Senate Health, Human Services and Senior Citizens Committee with
amendments. Id. On February 23, 2009, the Senate passed bill S119 with a vote of
22–16, and three days later, the General Assembly received it and referred it to the
Assembly Health and Senior Services Committee. Id. On June 4, 2009, the Senate
bill was reported out of the Assembly Health and Senior Services Committee with
amendments. Id. On January 7, 2010, the General Assembly further amended the
Senate bill on the assembly floor. Id. On January 11, 2010, just over two years after
the 2008–2009 legislative session when the medical-marijuana bills were introduced,
the General Assembly passed Senate bill S119 (as amended by the General Assembly
on January 7, 2010) with a vote of 48–14, and the Senate passed it with a vote of 25–
13. Id.
2
See
Active
State
Medical
Marijuana
Programs,
NORML,
http://norml.org/index.cfm?Group_ID=3391 (last visited Oct. 20, 2010). In fact,
medical-marijuana bills have been introduced in the New Jersey Legislature since
2004. See Gen. Assem. 804, 213th Leg., 2008–2009 Sess. (N.J. 2008); S. 119, 213th
Leg., 2008–2009 Sess. (N.J. 2008); Gen. Assem. 933, 212th Leg., 2006–2007 Sess. (N.J.
2006); S. 88, 212th Leg., 2006–2007 Sess. (N.J. 2006); Gen. Assem. 4501, 211th Leg.,
2004–2005 Sess. (N.J. 2004); S. 2200, 211th Leg., 2004–2005 Sess. (N.J. 2004); see also
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Seven days later, then-Governor Jon S. Corzine signed the measure
3
into law. Members of both major political parties introduced and
4
supported the Act throughout the long legislative process, which
signals that the legalization of medical marijuana and the desire to
provide relief to people suffering from debilitating medical conditions are not partisan issues.
5
Despite the widely accepted therapeutic value of marijuana,
possession, use, or cultivation of the drug, even for medicinal purposes, have been criminal offenses with harsh penalties under both
6
federal and New Jersey law for many years. Additionally, as a Schedule I controlled substance under the federal Controlled Substances
7
Act (CSA), marijuana cannot be prescribed by a physician or distri8
buted by a pharmacy. In fact, the federal government continues to
not only discourage but also hinder research on botanical medical
9
marijuana.
Medicinal marijuana advocates have had success at the state level. Between 1978 and 2008, thirty-six states and the District of Columbia enacted laws intended to provide suffering patients with legal

Phillip Smith, New Jersey Medical Marijuana Bill Heads for Senate Floor After Favorable
Committee Vote, DRUG WAR CHRONICLE (Dec. 19, 2008, 12:00 AM),
http://stopthedrugwar.org/chronicle/2008/dec/19/feature_new_jersey_medical_m
arij.
3
New Jersey Gov. John Corzine Signs Medical Marijuana Bill into Law, N.Y. DAILY
NEWS (Jan. 18, 2010), http://www.nydailynews.com/news/2010/01/18/2010-0118_new_jersey_gov_corzine_signs_.html. Interestingly, while some have stated that
Governor Chris Christie would have opposed the measure, others have reported that
he supports medical marijuana. Medical Marijuana Bill ‘Workable,’ N.J. Attorney General
Says,
NJ.COM
(Apr.
21,
2009),
http://www.nj.com/news/index.ssf/2009/04/medical_marijuana_bill_workabl.html
[hereinafter Medical Marijuana Bill]; Brian Thompson, Stunning Reversal at Medical
Marijuana
Trial,
NBC
NEW
YORK,
(Dec.
16,
2009),
http://www.nbcnewyork.com/news/local-beat/Stunner-at-Medial-Marijuana-Trial-inNJ-79447032.html.
4
See N.J. Gen. Assem. B. 804; N.J. S.B. 119; see also supra note 1.
5
See infra Part II.
6
See 21 U.S.C. §§ 841(a)(1), 844(a) (2006); see also N.J. STAT. ANN. §§ 2C:35-1 to 29, 2C:36-1 to -10 (West 2010).
7
21 U.S.C. § 812 (2006); see also discussion infra Part III.A.
8
United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 491 (2001); see
also 21 U.S.C. § 829 (2006) (detailing how drugs classified in Schedules II through V
may be prescribed and dispensed).
9
See Gardiner Harris, Researchers Find Study of Medical Marijuana Discouraged, N.Y.
TIMES, Jan. 19, 2010, at A14.
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10

access to marijuana. In 1996, California became the first state to
pass a law legalizing medical use of the drug, and twelve states fol11
lowed its lead. New Jersey is now the fourteenth state to remove
state-level criminal penalties for medical marijuana and recognize its
medicinal value. The NJCMA carves out a limited but necessary exemption from criminal liability for individuals who need marijuana to
ease the symptoms of debilitating illnesses when other treatment options do not work.
The NJCMA is among the most restrictive state medicalmarijuana laws in the nation and it was created to provide marijuana
to individuals with specific enumerated debilitating medical condi12
tions via a reasonable system that is highly regulated and extensively
13
overseen. New Jersey’s Attorney General at the time of passage,
14
Anne Milgram, deemed the NJCMA to be “workable.” This is important because for the legislation to be effective, it must have the
support of the state government and state and local law enforcement.
Additionally, public opinion in New Jersey overwhelmingly supports
15
the legalization of marijuana for medical use. According to a poll
conducted in May 2006, eighty-six percent of voters were convinced
that “seriously ill patients should have access to marijuana for medical
16
purposes if a physician recommends it.” Significantly, fifty-nine percent of New Jersey voters even said that they would defy current law

10

MARIJUANA POLICY PROJECT, STATE-BY-STATE MEDICAL MARIJUANA LAWS: HOW TO
REMOVE
THE
THREAT
OF
ARREST
10
(2008),
available
at
http://docs.mpp.org/pdfs/download-materials/SBSR_NOV2008_1.pdf.
11
See infra notes 154–55 and accompanying text.
12
See S. 119, 213th Leg., 2008–2009 Sess. (N.J. 2008) (as passed by both houses of
the N.J. Legislature on Jan. 11, 2010).
13
See infra Part IV.
14
Medical Marijuana Bill, supra note 3. Acknowledging existing concerns about
ensuring that the law allows access to marijuana only to those with debilitating medical conditions, Attorney General Milgram’s office “sent recommendations to the
governor on ways to guard against abuses.” Id.
15
See THE POLLING COMPANY, INC., MEDICAL MARIJUANA: STATEWIDE SURVEY OF 700
REGISTERED VOTERS OF NEW JERSEY 3 (June
2006),
available
at
http://www.pollingcompany.com/cms/files/DPANJ%20Medical%20Marijuana%20
Executive%20Summary.pdf.
16
Id. at 3. In fact, agreement on this issue “spanned demographic divides, with
no less than three-quarters of every major demographic group studied, including
members of all three political parties, endorsing access to medical marijuana with a
doctor’s recommendation.” Id. at 4. Further, when told that “the use of marijuana,
including for medical reasons, is illegal in New Jersey [but] about 11 other states now
allow seriously ill patients to have medical marijuana with a doctor’s recommendation . . . eighty-three percent indicated that patients in their own state should have
the same rights.” Id.
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to obtain the drug for a “close friend or family member [who] was
17
suffering from a condition that could be eased by marijuana.”
Finally, while federal policymakers remain ambivalent about the
18
wisdom of state medical-marijuana legalization, the Obama administration has taken a very different stance than previous administrations
regarding federal drug enforcement in states that have legalized ma19
rijuana for medical use. Thus, now is the time for states like New
Jersey to enact medical-marijuana legislation. Ultimately, reason,
compassion, and medical evidence support New Jersey’s elimination
of criminal penalties for the medical use of marijuana under state
law.
Part II of this Comment reviews the history of marijuana as medicine and the science behind the controversy of whether marijuana
has therapeutic value. Part III provides a brief overview of marijuana’s current status under federal and state law and discusses the interplay between the two. In Part IV, this Comment provides an overview and critique of the NJCMA and suggests ways in which the Act
can be improved.
II. MARIJUANA AS MEDICINE
A. Brief History of the Use of Marijuana for Medicinal Purposes
20

Marijuana, also known as cannabis or hemp, is one of the old21
est known psychoactive plants on earth. Marijuana grows as both a
22
weed and a cultivated plant all over the world. While it has only
been used as a medicine in the United States since the middle of the
1800s, marijuana has been used medicinally throughout the world for
23
thousands of years. The first evidence of the medical use of mariju17
Id. at 5. Seventy-one percent of those who responded agreed “with the New
Jersey state legislature passing a bill that would permit patients to possess ‘one ounce
of marijuana and six marijuana plants for medical purposes if they have a recommendation from a doctor,’ and forty-seven percent did so ‘strongly.’” Id. at 6.
18
See Harris, supra note 9, at A1.
19
See infra Part III.C.2.
20
The word is alternatively spelled “marihuana,” most often in U. S. government
literature. Throughout this Comment, “marijuana,” “marihuana,” and “cannabis”
may be used interchangeably to refer to the natural, botanical form of the substance.
21
LESTER GRINSPOON & JAMES BAKALER, MARIHUANA, THE FORBIDDEN MEDICINE 1
(rev. ed. 1997).
22
Id.
23
Id. at 3–7. “Cannabis may have been cultivated as long as ten thousand years
ago” and “has long been used as a medicine in India, China, the Middle East, Southeast Asia, South Africa, and South America.” Id. at 3. In addition to its therapeutic
properties, cannabis “fiber has been used to produce cloth and paper for centuries,”
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ana was published five thousand years ago, recommending cannabis
for “malaria, constipation, rheumatic pains, ‘absentmindedness,’ and
24
female disorders.” Cannabis “did not come into its own” as a medi25
cine in the West “until the middle of the nineteenth century.” In
1839, the first Western physician to take an interest in the medical
properties of cannabis, W.B. O’Shaughnessy, wrote about the plant’s
analgesic and muscle relaxant properties and called it “an anticonvul26
sive remedy of the greatest value.” Soon after, doctors in Europe
and the United States started to recognize marijuana’s therapeutic
potential and began prescribing cannabis “for a variety of physical
conditions”; preparations made from cannabis were available in drug
27
stores. Some doctors believed marijuana to be as effective a pain reliever as opium but with the added benefit of acting as an appetite
28
stimulant. Marijuana was also said to “subdue restlessness and an29
xiety and distract a patient’s mind in terminal illness.” Cannabis was
30
31
included in the United States Pharmacopoeia in 1850, and, between
and until the development of synthetic fibers, it “was the most important source of
rope.” Id. at 1. In fact, the Declaration of Independence was drafted on hemp paper.
See Christen D. Shepherd, Comment, Lethal Concentration of Power: How the D.E.A. Acts
Improperly to Prohibit the Growth of Industrial Hemp, 68 UMKC L. REV. 239, 261 n.33
(1999). Additionally, the oil in marijuana seeds that was once “used for lighting and
soap” is sometimes still used in the production of varnish, linoleum, and paint.
GRINSPOON & BAKALER, supra note 21, at 1.
24
GRINSPOON & BAKALER, supra note 21, at 3. The evidence was published “during the reign of the Chinese emperor Chen Nung.” Id. Throughout the world, cannabis or hemp (including its oil) has been recommended or used to treat, inter alia,
malaria, coughs, and urinary incontinence, “to quicken the mind, lower fevers, induce sleep, cure dysentery, stimulate appetite, improve digestion, relieve headaches,
and cure venereal disease.” Id. Marijuana might also be used to treat depression. Id.
25
Id. at 4. While marijuana did not “come into its own” in the West until the
1800s, “the first definite record of the marijuana plant in the New World dates from
1545 A.D., when Spaniards introduced it into Chile.” GARY J. MILLER, DRUGS AND THE
LAW: DETECTION, RECOGNITION & INVESTIGATION 405 (2nd ed. 1997). From the early
1600s until after the Civil War, the cannabis plant was a major crop in North America
primarily because of its use in the production of hemp fabric. See id. at 405–06.
26
GRINSPOON & BAKALER, supra note 21, at 4. After testing cannabis on animals
and satisfying himself that it was safe, O’Shaughnessey gave it to “patients suffering
from rabies, rheumatism, epilepsy, and tetanus.” Id. O’Shaughnessy created a “tincture of hemp (a solution of cannabis in alcohol, taken orally).” Id.
27
Id. at 4.
28
Id. at 5.
29
Id.
30
The U.S. Pharmacopeia is a non-governmental, not-for-profit public-health organization that serves as “an official public standards-setting authority for all prescription and over-the-counter medicines and other health care products manufactured or sold in the United States.”
See About USP, U.S. PHARMECOPEIA,
http://www.usp.org/aboutUSP/ (last visited Mar. 27, 2011). The health organization publishes the United States Pharmacopeia, an official compendium. USP–NF—An
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1840 and 1900, “more than one hundred papers were published in
Western medical literature recommending cannabis for ‘various ill32
nesses and discomforts.’”
By 1890, physicians in the United States began reducing their reliance on marijuana based, in part, on the fact that “the potency of
33
cannabis preparations was too variable.”
Instead, physicians prescribed more chemically stable and reliable synthetic drugs like aspi34
rin, chloral hydrate, and barbiturates. The advent of the hypodermic needle also resulted in increased use of opiates for fast pain
35
relief. Opiates, unlike hemp products, are water soluble, and, there36
fore, are easily administered by syringe. Despite its decline in use,
medical marijuana remained legal in the United States throughout
much of the twentieth century. In fact, not until 1970 did Congress
make the possession, use, or cultivation of marijuana illegal under
37
federal law.

Overview, U.S. PHARMECOPEIA, http://www.usp.org/USPNF/ (last visited Mar. 27,
2011). While many sources use “pharmacopoeia,” the current accepted spelling appears to be “pharmacopeia.”
31
Gregg A. Bilz, The Medical Use of Marijuana: The Politics of Medicine, 13 HAMLINE
J. PUB. L. & POL’Y 117, 118 (1992) (citing JEROME L. HIMMELSTEIN, THE STRANGE
CAREER OF MARIHUANA 22 (1983)). Marijuana was subsequently removed from the
U.S. Pharmacopeia in 1941. See GRINSPOON & BAKALER, supra note 21, at 8.
32
GRINSPOON & BAKALER, supra note 21, at 4 (citing MARIJUANA: MEDICAL PAPERS,
1839–1972 (T.H. Mikuriya, ed. 1973)); see also RICHARD E. ISRAELOWITZ & DARWIN
TELIAS, DRUG USE, POLICY, AND MANAGEMENT 96 (1998)
Among the recommended uses were as an analgesic (in the form of
tincture of hemp—a solution of cannabis in alcohol taken orally); as a
topical anesthetic for the mouth and tongue; and for problems and
discomfort related to tetanus, neuralgia, dismenorrhea (painful menstruation), convulsions, rheumatic and childbirth pain, asthma, postpartum psychosis, gonorrhea, and chronic bronchitis, for preventing
migraine attacks, certain kinds of epilepsy, depression, asthma, rheumatism, gastric ulcer, and drug addiction, particularly of morphine and
other opiate substances.
Id.
33
GRINSPOON & BAKALER, supra note 21, at 7.
34
Id.; see also ISRAELOWITZ & TELIAS, supra note 32, at 96.
35
GRINSPOON & BAKALER, supra note 21, at 7; see also ISRAELOWITZ & TELIAS, supra
note 32, at 96.
36
GRINSPOON & BAKALER, supra note 21, at 7; see also ISRAELOWITZ & TELIAS, supra
note 32, at 96. Even with use in decline, marijuana’s medicinal properties continued
to interest physicians, and in 1891, Dr. J.B. Mattison called cannabis “a drug that has
a special value in some morbid conditions and the intrinsic merit and safety of which
entitles it to a place it once held in therapeutics.” GRINSPOON & BAKALER, supra note
21, at 6 (citing J.B. Mattison, Cannabis Indicia as an Anodyne and Hypnotic, 61 ST. LOUIS
MED. SURGICAL J. 266 (1891)).
37
See infra Part III.A.
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B. The Controversy Behind the Science
Over the last hundred years, public opinion in the United States
38
has been divided on the medical value of marijuana. Anecdotal evi39
dence emerged in the late twentieth century suggesting that mariju40
ana has medicinal properties that provide relief from symptoms associated with numerous illnesses, including “AIDs wasting, spasticity
from multiple sclerosis, depression, chronic pain, nausea associated
41
42
43
44
with chemotherapy,” glaucoma, epilepsy, and migraines. Today
there are “well-recognized therapeutic uses for cannabis, and many
45
others
are
currently
under
investigation.”
The federal government and other opponents of marijuana legalization, however, have staunchly maintained a position that is reflected in U.S. law “that botanical marijuana is a dangerous drug
46
without any legitimate medical use.” In support of their position,
opponents emphasize that “marijuana intoxication can impair a per38
INST. OF MEDICINE, MARIJUANA AND MEDICINE: ASSESSING THE SCIENCE BASE 1 (Janet E. Joy et al., eds., 1999). “Some dismiss medical marijuana as a hoax that exploits
our natural compassion for the sick; others claim it is a uniquely soothing medicine
that has been withheld from patients through regulations based on false claims.” Id.
39
For instance, in the 1970s, people began to report that “marijuana relieved
nausea associated with chemotherapy” and in the 1980s, “when the AIDs epidemic
spread . . . patients found that marijuana sometimes relieved their symptoms, most
dramatically those associated with AIDs wasting.” Id. at 18.
40
Susan Corey, Recent Developments in the Therapeutic Potential of Cannabinoids, 24 P.
R. HEALTH SCI. J. 19, 19 (2005).
41
See INST. OF MEDICINE, supra note 38, at 23 (stating that “patients who reported
their experience with marijuana at the public workshops said that marijuana provided them with great relief” of symptoms associated with these illnesses).
42
See GRINSPOON & BAKALER, supra note 21, at 40–57.
43
See id. at 58–67.
44
See id. at 106–09.
45
Ruth C. Stern & J. Herbie DiFonzo, The End of the Queen’s Race: Medical Marijuana in the New Century, 27 QUINNIPIAC L. REV. 673, 693 (2009).
46
MARK EDDY, CONG. RESEARCH SERV., RL 33211, MEDICAL MARIJUANA: REVIEW AND
ANALYSIS OF FEDERAL AND STATE POLICIES 24 (2009) (internal citation omitted). Ironically, “in 1978, the FDA created the Investigational New Drug (IND) Compassionate
Access Program, allowing patients whose serious medical conditions could be relieved only by marijuana to apply for and receive marijuana from the federal government.” Id. at 8. The program “was not a clinical trial to test the drug for eventual
approval,” but it was instead a way “for the government to provide medical marijuana
to patients demonstrating necessity.” Id. at 8, n.32. Over the years, less than one
hundred patients “were admitted to the program for conditions including chemotherapy induced nausea and vomiting (emesis), glaucoma, spasticity, and weight
loss,” and “in 1992, in response to a large number of applications from AIDS patients
who sought to use medical cannabis to increase appetite and reverse wasting disease,
the George H.W. Bush administration closed the program to all new applicants.” Id.
at 8. “Several previously approved patients remain in the program today and continue to receive their monthly supply of government-grown medical marijuana.” Id.
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son’s coordination and decision-making skills and alter behavior” and
that “[c]hronic marijuana smoke can adversely affect the lungs, the
cardiovascular system, and possibly the immune and reproductive sys47
tems.”
C. The Science Behind the Controversy: The Benefits of Botanical
Medical Marijuana Often Outweigh the Risks
Underlying much of the controversy is the fact that proponents
of medical marijuana seek to legalize use of the actual plant rather
than a synthetic version of its primary chemical, tetrahydrocannabinol (THC). Marijuana generally “refers to the dried flowers, leaves,
48
stems and seeds of the Cannabis sativa plant.” It contains over 460
49
known compounds, including at least sixty chemicals known as can50
nabinoids. Among these are delta-9 THC, the primary psychoactive
component in marijuana, and cannabigerol, cannabinol, and canna51
bidiol—non-psychoactive cannabinoids. While THC is the primary
psychoactive component of marijuana, not all of the effects of mari52
juana on the human body are the result of THC.
Studies show that “cannabinoids produce most of their effect” by
binding to receptors on the surface of certain types of cells, each of
which only recognizes “a few specific molecules, known collectively as
53
ligands.” “When the appropriate ligand binds to its receptor, it typi54
cally sets off a chain of biochemical reactions inside the cell.” The
55
receptors that bind cannabinoids are “cannabinoid receptors.” To
date, researchers have discovered two types of cannabinoid receptors:
56
CB1 and CB2. CB1 “mediates the central nervous system,” and CB2
47
Id. at 24 (citing Exposing the Myth of Medical Marijuana, DEP’T OF JUSTICE, DRUG
ENFORCEMENT AGENCY, http://www.justice.gov/dea/ongoing/marijuanap.html (last
visited Feb. 19, 2010)).
48
Marijuana as Medicine: Consider the Pros and Cons, MAYO CLINIC (Oct. 27, 2009),
http://www.riversideonline.com/health_ reference/Articles/GA00014.cfm.
49
GRINSPOON & BAKALER, supra note 21, at 2.
50
MAYO CLINIC, supra note 48.
51
See id.; see also ALLISON MACK & JANET JOY, MARIJUANA AS MEDICINE? THE SCIENCE
BEYOND THE CONTROVERSY 27 (2001).
52
MACK & JOY, supra note 51, at 8 (“[A] complex mixture of chemical compounds
[exists in the marijuana plant and] . . . . the effects of marijuana on the body include
those of THC . . . not all of marijuana’s effects are necessarily due to THC alone.”).
53
Id. at 27.
54
Id.
55
Id. at 28.
56
AM. COLL. OF PHYSICIANS, POSITION PAPER: SUPPORTING RESEARCH INTO THE
THERAPEUTIC
ROLE
OF
MARIJUANA
4
(2008),
available
at
http://www.csdp.org/research/medmarijuana.pdf.
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“occurs outside the [central nervous system] and is believed to have
57
anti-inflammatory and immunosuppressive activity.”
In 1985, the Food and Drug Administration (FDA) approved
Marinol (Dronabinol), a synthetic form of THC encapsulated in se58
same oil, to treat “nausea and vomiting associated with cancer chemotherapy patients who fail to respond to conventional antiemetic
59
treatments.” The FDA later approved Marinol “for the treatment of
60
anorexia associated with weight loss in patients with AIDs.”
Although Marinol was originally a Schedule II drug, the DEA moved it
to Schedule III in 1999 after it and the “Department of Health and
61
Human Services found little evidence of illicit abuse of the drug.”
In 2006, the FDA approved Cesamet (Nabilone), another synthetic
cannabinoid similar to THC, for the treatment of chemotherapy62
63
induced nausea and vomiting. Cesamet is a Schedule II drug. In
2005, Canada approved Sativex, “a whole plant extract that contains
64
THC and cannabidiol,” for use in treating neuropathic pain asso65
ciated with multiple sclerosis (MS). Canada also approved the oral
spray, which is absorbed in the patient’s mouth, as “adjunctive analgesic treatment in patients with advanced cancer who experience
moderate to severe pain during the highest tolerated dose of strong
66
opioid therapy” in 2007. It is currently in clinical trials, being studied for the treatment of patients with advanced cancer whose pain is
67
not being relieved by strong opioid medications.
The FDA’s approval of synthetic cannabinoid-based medications
evidences that marijuana’s components have therapeutic properties.
But for a subset of patients, the natural plant is superior because
smoking may actually be a preferred drug-delivery system. Oral THC
57

Id.
INST. OF MEDICINE, supra note 38, at 202.
59
EDDY, supra note 46, at 8.
60
Id.
61
Id. In contrast, marijuana in its natural form is a Schedule I drug. See infra
Part III.A for a discussion about the scheduling of drugs under federal law.
62
Valeant Receives FDA Marketing Approval for Cannabinoid Cesamet, DRUGS.COM (May
16, 2006), http://www.drugs.com/ news/valeant-receives-fda-marketing-approvalcannabinoid-cesamet-1794.html.
63
Cesamet, RXLIST.COM, http://rxlist.com/cesamet-drug.htm (last visited Mar. 31,
2010).
64
Wendy Koch, Spray Alternative to Pot on the Market in Canada, USA TODAY, June
24, 2005, at 4A.
65
Sativex, GW PHARMS., http://gwpharm.com/sativex.asp (last visited Jan. 4,
2010).
66
Id.
67
Id.
58
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is slower to take effect than smoked marijuana and “produces more
pronounced, and often unfavorable, psychoactive effects that last
68
much longer than those experienced with smoking.” In contrast,
“smoked THC is quickly absorbed into the blood and effects are ex69
perienced immediately.” The fast-acting nature of smoked marijuana also “allows patients to easily determine the right dose for symp70
tom relief.”
With oral cannabinoid medications, patients cannot
71
similarly “self-titrate” because “absorption is highly variable and un72
predictable and often delayed” when THC is taken orally. For patients whose severe nausea and vomiting prevent them from taking
anything orally, such as those undergoing cancer chemotherapy, in73
halation is the only alternative. Additionally, some doubt that synthetics are sufficient substitutes: “[S]ingle-cannabinoid, synthetic
pharmaceuticals like Marinol are poor substitutes for the whole marijuana plant, which contains more than 400 known chemical compounds, including about 60 active cannabanoids in addition to
74
THC.” Finally, natural marijuana is cheaper and easier to manufacture than synthetic cannabioid-based medications, which are expen75
sive.
Modern medical evidence supports using marijuana to treat the
symptoms of a range of debilitating illnesses, including pain, loss of
76
appetite, nausea, and spasticity. While some FDA-approved medications are arguably “more effective” than marijuana, some people may
not respond well to other medicine—they may not experience relief

68

AM. COLL. OF PHYSICIANS, supra note 56, at 7 (citing J. Beal et al., Long-Term Efficacy and Safety of Dronabinol for Acquired Immunodeficiency Syndrome-Associate Anorexia,
14(1) J. OF PAIN AND SYMPTOM MGMT. 7–14 (1997)).
69
Id.
70
Lester Grinspoon, Puffing is the Best Medicine, L.A. TIMES, May 5, 2006, at B13.
71
See id.
72
Jill U. Adams, A Balm for Pain, L.A. TIMES, Aug. 18, 2008, at F6 (quoting Dr.
Igor Grant, a University of California, San Diego psychiatrist who directs the university’s Center for Medicinal Cannabis Research).
73
See EDDY, supra note 46, at 29.
74
Id. at 26. In addition to the fact that “many patients have found that they benefit more from the whole plant than from any synthetically produced chemical derivative,” proponents argue that “scientists are a long way from knowing for sure which
ones, singly or in combination, provide which therapeutic effects.” Id. (internal citation omitted).
75
Id. at 26–27 (noting that Marinol currently retails for approximately $17 per
pill).
76
See AM. COLL. OF PHYSICIANS, supra note 56, at 3–6.
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or may be unable to tolerate the side effects—or may simply respond
77
better to marijuana.
In short, the natural form of marijuana may be preferable for a
small subset of patients for whom current products are ineffective, or
at least less effective, than marijuana. For example, many cancer patients suffer from “profound nausea and vomiting” as a side effect of
78
chemotherapy.
The cannabinoids in marijuana are an effective
treatment for this debilitating adverse effect, which the FDA approval
of Marinol and Cesamet evidences. Additionally, a review of thirty
clinical studies published in the European Journal of Cancer Care reported that cannabinoid drugs have an anti-emetic efficacy superior
79
to conventional anti-nausea drugs.
In AIDS and HIV patients, marijuana relieves a number of symp80
toms, including wasting (cachexia) and pain. It can also improve

77

INST. OF MEDICINE, supra note 38, at 3–4.
GRINSPOON & BAKALER, supra note 21, at 25.
Retching (dry heaves) may last for hours or even days after each treatment, followed by days and even weeks of nausea. Patients may break
bones or rupture the esophagus while vomiting. The sense of a loss of
control can be emotionally devastating. Furthermore, many patients
eat almost nothing because they cannot stand the sight or smell of
food. As they lose weight and strength, they find it more and more difficult to sustain the will to live.
Id. “For many patients, the side effects of chemotherapy seem worse than the cancer
itself, and they discontinue treatment, not only to eliminate the discomfort but also
to regain control over their lives.” Id.
79
F.C. Machado Rocha et al., Therapeutic Use of Cannabis Sativa on ChemotherapyInduced Nausea and Vomiting Among Cancer Patients: Systematic Review and Meta-Analysis,
J.
OF
CANCER
CARE
431,
440
(2008),
available
at
17
EUR.
http://www.phillynorml.org/documents/legis_files/08_Review%20Cannabis%20sati
va%20chemotherapy%20enemia_Rocha_EJCC.pdf; see also Martin R. Tramèr et al.,
Cannabinoids for Control of Chemotherapy Induced Nausea and Vomiting: Quantitative Systematic Review, 323 BRIT. MED. J. 16, 20 (2001) (finding cannabinoids to be superior to
conventional antiemetics after chemotherapy, that patients preferred them, and that
“[i]n selected patients, cannabinoids may be useful as mood enhancing adjuvants for
the control of chemotherapy related sickness”). The study authors stated that “potentially serious adverse effects . . . are likely to limit their widespread use,” but also
noted that “some side effects could be classified as potentially beneficial (for instance, a sensation of a ‘high,’ euphoria, and drowsiness, sedation, or somnolence).”
Id. at 18, 20.
80
“Wasting syndrome in acquired immune deficiency syndrome (AIDS) patients
is defined by the Centers for Disease Control and Prevention as the involuntary loss
of more than 10% of baseline average body weight in the presence of diarrhea or
fever of more than 30 days that is not attributable to other disease processes.” INST.
OF MEDICINE, supra note 38, at 154 (internal citation omitted).
78
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mood and sleep. The FDA’s approval of Marinol for the treatment
of “anorexia associated with weight loss in patients with AIDS” evidences the fact that marijuana and its cannabinoids can stimulate the
82
appetite. Additionally, according to the American College of Physicians, “research supporting THC as an effective appetite stimulant
and antiemetic is abundant,” and “[c]linical trials have demonstrated
that both oral and smoked marijuana stimulate appetite, increase caloric intake, and result in weight gain among patients experiencing
83
HIV wasting.” One double-blind study published in the Journal of
Acquired Immune Deficiency Syndromes compared the effects of Marinol
and marijuana on cognitive performance, mood, appetite stimula84
tion, and sleep in HIV-positive marijuana smokers. It found that
Marinol and marijuana both “produced substantial and comparable
increases in food intake” and “improved mood without producing
disruptions in psychomotor functioning,” but that “[smoked] mariju85
ana has the added benefit of improving sleep ratings.” The study also noted that ninety-three percent of the patients surveyed preferred
86
smoked marijuana to Marinol. Finally, “neither marijuana nor [Marinol] significantly altered performance on any of the tasks (e.g.,
measures of learning, memory, vigilance, psychomotor ability),” and
the researchers stated that the “present data indirectly suggest that
tolerance selectively develops to the cognitive effects of marijuana
87
and [Marinol].”
Researchers have also found that smoked marijuana is welltolerated and effective in treating neuropathic pain in patients with
88
HIV-associated sensory neuropathy. Although anticonvulsants can
also be effective, “some patients fail to respond or cannot tolerate”
89
them.
Marijuana is also effective in the treatment of symptoms of MS.
“[P]ainful muscle spasms are among the most common and distress81

See Margaret Haney et al., Dronabinol and Marijuana in HIV-Positive Marijuana
Smokers: Caloric Intake Mood and Sleep, 45 J. ACQUIR. IMMUNE DEFIC. SYNDR. 545, 552
(2007).
82
See EDDY, supra note 46, at 8.
83
AM. COLL. OF PHYSICIANS, supra note 56, at 4 (internal citation omitted).
84
Haney et al., supra note 81, at 545.
85
Id. at 552.
86
Id.
87
Id. at 550–52.
88
Donald I. Abrams et al., Cannabis in Painful HIV-Associated Sensory Neuropathy: A
Randomized Placebo-Controlled Trial, 68 NEUROLOGY 515, 515 (2007). HIV-associated
sensory neuropathy is a painful nerve disorder. See id.
89
Id. (internal citation omitted).
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ing symptoms,” severely influencing patients’ quality of life. Current
91
therapeutic options are often expensive or unavailable. Most importantly, these drugs do not wholly ameliorate quality of life issues—
“available oral anti-spasticity medications often only give partial relief
92
and have gastrointestinal or psychotropic side effects.” According to
researchers, “[a]necdotal evidence, preclinical data, small clinical reports, and phase 2 trials, suggest that cannabis derivatives may play a
useful role in alleviating muscle spasms, tremors, pain, and bladder
93
dysfunction associated with MS.” In 2005, a “randomized, doubleblind, placebo-controlled cross-over study of an orally administered
standardized Cannabis sativa plant extract in patients with MSinduced spasticity . . . found the extract to be safe and well tolerated
94
and that it may reduce spasm frequency” and increase mobility. The
study also noted that “beneficial effects upon sleep” were consistent
95
with other studies. In another study, researchers found smoked ma96
rijuana to be “superior to placebo in reducing spasticity and pain.”
Additionally, while the National Multiple Sclerosis Society has not yet
recommended that medical marijuana be made widely available to
people with MS, it has stated that “it is clear that cannabinoids have
potential both for the management of MS symptoms such as pain and
97
spasticity, as well as for neuro-protection.”
Marijuana and its constituent cannabinoids are not completely
without their side effects, which include diminished psychomotor
performance, unpleasant feelings, and “short term immunosuppres-

90
C. Vaney et al., Efficacy, Safety, and Tolerability of an Orally Administered Cannabis
Extract in the Treatment of Spasticity in Patients with Multiple Sclerosis: A Randomized,
Double-Blind, Placebo-Controlled, Crossover Study, 10 MULTIPLE SCLEROSIS 417, 417 (2004)
(citing L. Provinciali et al., A Multidimensional Assessment of Multiple Sclerosis: Relationship Between Disability Domains, 100 ACTA NEUROL SCAND 156–62 (1999)).
91
Id.
92
Id.
93
Id. (internal citation omitted).
94
Id. at 421, 423.
95
Id. at 422.
96
Jody Corey-Bloom et al., Short-Term Effects of Medicinal Cannabis on Spasticity in
Multiple Sclerosis, http://cmcr.ucsd.edu/images/pdfs/Corey-Bloom_poster_1.pdf
(last visited May 28, 2011). Study investigators noted, however, that “although generally well tolerated” smoked cannabis “resulted in statistically significant cognitive
effects.” Id.
97
NAT’L MULTIPLE SCLEROSIS SOCIETY, EXPERT OPINION PAPER: RECOMMENDATIONS
REGARDING THE USE OF CANNABIS IN MULTIPLE SCLEROSIS (2008), available at
http://www.nationalmssociety.org/for-professionals/healthcareprofessionals/publications/expert-opinion-papers/index.aspx.
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sive effects.” But no “case of human death by cannabis poisoning”
99
has ever been published. Some have even stated that “[m]arihuana
in its natural form is possibly the safest therapeutically active sub100
stance known to humanity.”
According to the Institute of Medicine, “except for the harms associated with smoking, the adverse effects of marijuana use are within the range of effects tolerated for
101
other medications.”
Despite conflicting evidence, some have argued that marijuana
smoking causes cancer. In fact, “[l]ong term exposure to cannabis
smoke has long been thought to increase the risk of respiratory can102
cers as well as cancers of the mouth, tongue, and esophagus.” Marijuana smoke does contain “many of the components of tobacco
smoke,” and far more tar “can be deposited in the lungs” of a marijuana smoker than that of a cigarette smoker with cigarettes of compa103
rable weight.
This is due primarily to the fact that “[m]arijuana
cigarettes usually do not have filters, and marijuana smokers typically
develop a larger puff volume, inhale more deeply, and hold their
104
breath several times longer than tobacco smokers.”
But in a study funded by the National Institute of Health’s National Institute on Drug Abuse, Dr. Donald Tashkin, a pulmonologist
at the University of California at Los Angeles, found that “[p]eople
who smoke marijuana—even heavy, long-term marijuana users—do
105
not appear to be at an increased risk of developing lung cancer” or
other head and neck cancers, including cancer of the tongue, mouth,
106
throat or esophagus. The heaviest smokers that participated in the
98
INST. OF MEDICINE, supra note 38, at 5. The authors note that “the short term
immunosuppressive effects are not well established, but if they exist, they are not
likely great enough to preclude a legitimate medical use.” Id.
99
Stern & DiFonzo, supra note 45, at 700 (citing Wayne Hall & Nadia Solowij,
Adverse Effects of Cannabis, 352 LANCET 1611, 1612 (1998)).
100
GRINSPOON & BAKALER, supra note 21, at 138.
101
INST. OF MEDICINE, supra note 38, at 5.
102
Stern & DiFonzo, supra note 45, at 701 (citing Wayne Hall et al., Cannabinoids
and Cancer: Causation, Remediation, and Palliation, 6 LANCET ONCOLOGY 35, 37 (2005)).
103
INST. OF MEDICINE, supra note 38, at 111 (internal citations omitted).
104
Id. (citation omitted).
105
Press Release, Am. Thoracic Soc’y, Study Finds No Link Between Marijuana
Use
and
Lung
Cancer
(May
23,
2006),
available
at
http://www.thoracic.org/sections/publications/pressreleases/conference/articles/2006/press-releases/study-finds-no-link-betweenmarijuana-use-and-lung-cancer.html). These findings were presented at the American Thoracic Society International Conference on May 23, 2006. Id.
106
Marc Kaufman, Study Finds No Cancer-Marijuana Connection, WASH. POST, May
26, 2006, at A3; Am. Thoracic Soc’y, supra note 105; see also Tashkin DP et al., Mariju-
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study had smoked more than twenty-two-thousand marijuana ciga107
rettes in their lives, an amount Dr. Tashkin described as “enorm108
ous.” The results surprised Dr. Tashkin, who has studied marijuana
for more than thirty years, because “previous studies found that marijuana tar has 50 percent higher concentrations of chemicals linked to
cancer than tobacco cigarette tar” and because “marijuana users inhale more deeply and generally hold smoke in their lungs longer
than tobacco smokers, exposing them to dangerous chemicals for a
109
longer time.” According to Dr. Tashkin, a possible explanation for
the finding is that “THC . . . may encourage aging cells to die earlier
110
and therefore be less likely to undergo cancerous transformation.”
Ironically, “[f]ederal health and drug enforcement officials have
widely used Tashkin’s previous work on marijuana to make the case
111
that the drug is dangerous.”
Other studies have, however, found an increased cancer risk associated with smoking marijuana. A systematic review of “studies assessing the impact of marijuana smoking on lung premalignant findings and lung cancer” concluded the same year as the Tashkin study
stated that
[g]iven the prevalence of marijuana smoking and studies predominantly supporting biological plausibility of an association of
marijuana smoking and lung cancer on the basis of molecular,
cellular, and histopathologic findings, physicians should advise
patients regarding potential adverse health outcomes until fur-

ana Use and Lung Cancer: Results of a Case-Control Study, UKCIA, May 24, 2006,
http://www.ukcia.org/research/MjUseAndLungCancer.php.
107
Am. Thoracic Soc’y, supra note 105.
108
Neil Osterweill, ATS: Marijuana Smoking Found Non-Carcinogenic, MEDPAGE
TODAY
(May
24,
2006)
http://www.medpagetoday.com/HematologyOncology/LungCancer/3393.
109
Kaufman, supra note 106.
110
Am. Thoracic Soc’y, supra note 105. Further, in regard to the effect of marijuana smoking on lung health, according to Dr. Tashkin, “we can be close to concluding that smoking marijuana by itself does not lead to [chronic obstructive pulmonary
disease].” Donald P. Tashkin, Does Smoking Marijuana Increase the Risk of Chronic Obstructive Pulmonary Disease?, 180 CANADIAN MED. ASSOC. J. 797, 798 (2009). “COPD
(chronic obstructive pulmonary disease) is a serious lung disease which makes it hard
to breathe. Also known by other names, such as emphysema or chronic bronchitis,
COPD is now the 4th leading cause of death in the United States and also causes
long-term disability.” Chronic Obstructive Pulmonary Disease, NAT’L HEART LUNG AND
BLOOD INST., http://www.nhlbi.nih.gov/health/public/lung/copd/ (last visited Mar.
27, 2011).
111
Kaufman, supra note 106.
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ther rigorous studies are performed that permit definitive conclu112
sions.

Another study published in the European Respiratory Journal in 2008
reportedly found a fivefold increase in risk of lung cancer in individuals who smoked marijuana daily for ten years but “no effect in less
113
heavy users.”
Responding to these study results, Dr. Tashkin attributed what he referred to as the “vastly inflated estimates” to the
114
small sample size.
More clinical research is needed to establish definitively whether
the medical use of marijuana is detrimental to the lungs or leads to
an increase in lung cancer. Unquestionably, however, for some terminally ill patients, the immediate benefits of medical marijuana
115
outweigh the risk of potentially developing lung cancer.
Even if
smoking cannabis does affect lung health, patients can lessen the risk
of harm by using a vaporizer, which heats marijuana enough to release the cannabinoids without combustion and the “attendant
116
smoke toxins.” In fact, researchers have found that “vaporization of
117
cannabis is a safe and effective mode of delivery of THC.” Patients
118
can also cook and eat marijuana in its botanical form.
Opponents of the medical use of marijuana have also pointed to
the effect of marijuana on the immune system, which could be particularly dangerous to patients with compromised immune systems,
such as those living with AIDS or cancer. But the “effect is difficult to
119
understand because studies are contradictory.”
Some studies have
120
shown that “marijuana weakens the immune system” while others
have found that “cannabis stimulates the immune system and plays an

112
Reena Mehra et al., A Systematic Review: The Association Between Marijuana Smoking and Lung Cancer, 166 ARCH. INTERN. MED. 1359, 1367 (2006).
113
Jill U. Adams, Damaging Habit?, L.A. TIMES, Aug 18, 2008, at F6.
114
Id.
115
See INST. OF MEDICINE, supra note 38, at 159 (“Terminal cancer patients pose
different issues. For those patients the medical harms associated with smoking is of
little consequence. For terminal patients suffering debilitating pain or nausea and
for whom all indicated medications have failed to provide relief, the medical benefits
of smoked marijuana might outweigh the harm.”).
116
D.I. Abrams et al., Vaporization as a Smokeless Cannabis Delivery System: A Pilot
Study, 82 CLINICAL PHARMACOLOGY & THERAPEUTICS 571, 571 (2007).
117
Id.
118
See EDDY, supra note 46, at 29.
119
Stern & DiFonzo, supra note 45, at 701–02.
120
See Exposing the Myth of Medical Marijuana, supra note 47 (citing I. B. Adams et
al., Cannabis: Pharmacology and Toxicology in Animals and Humans, 91 ADDICTION 1585,
1585–1614 (1996)).
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important role in controlling immune responses.” Some have criticized the studies that have shown immune suppression as misleading
because of the “very high concentrations of drug used to produce”
122
the results.
Ultimately, no conclusive determination can be made
as to marijuana’s impact on the immune system.
Opponents and public policy makers involved in the “war on
drugs” continue to hold that marijuana is a “gateway” drug because
123
“most users of other illicit drugs have used marijuana first.”
But
“there is no conclusive evidence that the drug effects of marijuana
124
are causally linked to the subsequent abuse of other illicit drugs.”
Furthermore, the Institute of Medicine has noted that any evidence
supporting the “gateway” theory is inapplicable to medical marijuana
and that whether “medical availability would increase drug abuse” is
“beyond the issues normally considered for medical use of drugs and
should not be a factor in evaluating the therapeutic potential of mari125
juana or cannabinoids.”
Data from states with medical-marijuana laws have also consistently shown that legalization of medical marijuana does not send the
126
wrong message to children or increase recreational use of the drug.
According to a study by the Marijuana Policy Project advocacy organization, “data shows that no state with a medical marijuana law has experienced an increase in youth marijuana use since their law’s
enactment,” and “all states have reported overall decreases—
127
exceeding 50% in some age groups.”
Additionally, legalizing the
medical use of marijuana does not decriminalize recreational use of
the drug; people who use marijuana for recreational purposes are
still subject to federal and state criminal penalties.

121
Stern & DiFonzo, supra note 45, at 702 (citing J. Ludovic Croxford et al., Cannabinoids and the Immune System: Potential for the Treatment of Inflammatory Disease?, 166
J. NEUROIMMUNOLOGY 3, 4 (2005)). Additionally, in one study, “oral or smoked cannabinoids did not prove unsafe to patients infected with HIV.” Id. (citing Oliver Ulrich et al., Immune Control by Endocannabinoids—New Mechanisms of Neuroprotection?,
184 J. NEUROIMMUNOLOGY 127, 129 (2006)).
122
See Leo E. Hollister, Marijuana and Immunity, 24 J. OF PSYCHOACTIVE DRUGS
159,159–63 (1992).
123
INST. OF MEDICINE, supra note 38, at 6 (“[M]ost users of other illicit drugs have
used marijuana first.”).
124
Id.
125
Id. at 7.
126
See KAREN O’KEEFE ET AL., MARIJUANA POLICY PROJECT, MARIJUANA USE BY YOUNG
PEOPLE: THE IMPACT OF STATE MEDICAL MARIJUANA LAW (2008), available at
http://www.phillynorml.org/documents/legis_files/TeenUseReport_0608.pdf.
127
Id. at 1.
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A large number of organizations “support the use of marijuana
128
as a medicine,” and many more support medical-marijuana re129
search, including the Institute of Medicine and the American Col130
lege of Physicians (ACP). The ACP also advocates reviewing marijuana’s Schedule I classification and protecting patients using
marijuana in compliance with state law from federal criminal prose131
cution.
The bottom line is that marijuana and its constituent cannabinoids can be superior to available alternatives for symptom relief in certain patient populations. While there are health risks associated with
smoking marijuana, the benefits appear to outweigh the harms for
some patients with debilitating medical conditions, such as the terminally ill. As the Leukemia and Lymphoma Society has stated, “[I]t
cannot seriously be contested that there exists a small but significant
class of individuals who suffer from painful chronic, degenerative,
and terminal conditions, for whom marijuana provides uniquely ef132
fective relief.”
Citizens of New Jersey will now have access to that
relief.
III. LEGAL BACKGROUND
A. Federal Prohibition of Marijuana Under the Controlled
Substances Act
The possession, distribution, or cultivation of marijuana, even
for medical purposes, violates the federal Controlled Substance Act
(CSA) and Title II of the Comprehensive Drug Abuse Prevention and

128

See Health Organizations’ Endorsements, NAT’L ORG. FOR THE REFORM OF
MARIJUANA LAWS (NORML), http://norml.org/index.cfm?Group_ID=3388 (last updated June 17, 2004). These organizations include the American Academy of Family
Physicians, AIDS Action Council, the American Medical Student Association, the
American Nurses Association, the American Preventive Medical Association, the
American Public Health Association, the National Association for Public Health Policy, the New England Journal of Medicine, and the New Jersey State Nurses Association. Quick Reference, NAT’L ORG. FOR THE REFORM OF MARIJUANA LAWS (NORML),
http://norml.org/index.cfm?Group_ID=3389 (last updated June 16, 2008).
129
Id. This includes the American Cancer Society. Id.
130
See INST. OF MEDICINE, supra note 38, at 10–11; AM. COLL. OF PHYSICIANS, supra
note 56, at 3.
131
AM. COLL. OF PHYSICIANS, supra note 56, at 3.
132
EDDY, supra note 46, at 26 (citing Brief for the Leukemia and Lymphoma Society et al. as Amici Curiae Supporting Respondents at 4, Gonzales v. Raich, 545 U.S. 1
(2005) (No. 03-1454)).
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133

Control Act of 1970. In fact, the CSA applies even to entirely intras134
tate marijuana-related activities.
Under the CSA, controlled substances are categorized into five schedules “based on their accepted
medical uses, the potential for abuse, and their psychological and
135
physical effects on the body.” Marijuana is classified as a Schedule I
136
Schedule I drugs are those considered to
controlled substance.
have “a high potential for abuse,” to lack “currently accepted medical
use in treatment,” and to lack accepted safety for use under medical
137
supervision.
“By classifying marijuana as a Schedule I drug, as opposed to listing it on a lesser schedule, the manufacture, distribution,
or possession of marijuana became a criminal offense, with the sole
exception being use of the drug as part of a Food and Drug Adminis138
tration pre-approved research study.” Additionally, as a Schedule I
drug, physicians may not prescribe and pharmacists are precluded
139
from dispensing marijuana.
Simple possession of marijuana for
140
personal use is a misdemeanor under federal law that carries a sen-

133
21 U.S.C. § 841(a)(1) (2006) (making it unlawful to knowingly or intentionally
“manufacture, distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance” except as authorized by this title); id. §
844(a) (making it unlawful to knowingly or intentionally possess a controlled substance); id. § 812 Schedule I (c)(10) (classifying marijuana as a Schedule I controlled
substance).
134
Congress is authorized to enact laws regulating interstate commerce under the
Commerce Clause of the United States Constitution. See U.S. CONST. art. 1, § 8, cl. 3.
Congress exercised its Commerce Clause power when it enacted the CSA. See Tammy L. McCabe, Comment, It’s High Time: California Attempts to Clear the Smoke Surrounding the Compassionate Use Act, 35 MCGEORGE L. REV. 545, 547 (2004) (finding that
local cultivation and distribution of controlled substances not integral to the flow of
interstate commerce nonetheless have a “substantial and direct effect” on interstate
commerce and contribute to the swelling of interstate traffic of controlled substances
(citing 21 U.S.C.A. § 801(3)–(6) (West 1999))). The CSA applies to entirely “intrastate marijuana-related activities, including cultivation, possession, transportation and
distribution of marijuana” in any state. See id.; see also Gonzales v. Raich, 545 U.S. 1, 9
(2005) (“Congress’ Commerce Clause authority includes the power to prohibit the
local cultivation and use of marijuana in compliance with California law.”).
135
Gonzales, 545 U.S. at 13 (citing 21 U.S.C. §§ 811, 812 (2000)); see also 21 U.S.C.
§ 812 (2006) (listing the criteria for each schedule).
136
§ 812 Schedule I(c)(10).
137
§ 812(b)(1). In contrast, drugs with recognized medical uses, such as opium,
cocaine, and amphetamine, were assigned to Schedules II through V, depending on
their potential for abuse. EDDY, supra note 46, at 3 (citation omitted); see also § 812.
138
Gonzales, 545 U.S. at 14 (citing 21 U.S.C. §§ 823(f), 841(a)(1), 844(a) (2000);
United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 490 (2001)).
139
See 21 U.S.C. § 829 (2006) (detailing how drugs classified in Schedules II
through V may be prescribed and dispensed); see also Oakland Cannabis Buyers’ Coop.,
532 U.S. at 491–92.
140
See H.R. REP. NO. 91-1444 (1970), reprinted in 1970 U.S.C.C.A.N. 4566, 4570–77.
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tence of up to one year in federal prison and a maximum fine of
141
$100,000 for a first offense. Furthermore, the cultivation of mariju142
ana is a felony under federal law; the growth of just one plant carries up to five years in federal prison and a fine of up to $250,000 for
143
a first offense. Despite the widespread recognition of the potential
144
therapeutic benefits of marijuana, repeated attempts to remove ma145
rijuana from the CSA or have it re-scheduled on the federal level
146
have failed.
B. The States Take Action: A Brief Overview of State MedicalMarijuana Laws
Medical-marijuana advocates have had greater success with legalization at the state level. Between 1978 and 2008, thirty-six states and
the District of Columbia enacted some type of medical-marijuana
141

See 21 U.S.C. § 844(a) (2006); 18 U.S.C. § 3571(b)(5) (2006).
See 21 U.S.C. § 802(15) (2006) (defining “manufacture” to include “production” of a drug); § 802(22) (defining “production” to include, inter alia, cultivation or
growing of a controlled substance); see also United States v. Angel, 576 F.3d 318, 321
n.2 (6th Cir. 2009) (“The manufacture or cultivation of marijuana is a felony offense
under . . . federal . . . law.” (citing § 841(a)(1), (b)(1)(D)(1))).
143
Id. § 841(b)(1)(D).
144
See supra Part II.
145
The CSA authorizes the Attorney General to determine appropriate scheduling of controlled substances and to transfer substances between schedules if it finds
that a drug does not meet the criteria for an individual schedule. See 21 U.S.C. § 811
(2006). The Attorney General has delegated this authority to the Administrator of
the Drug Enforcement Administration. 28 C.F.R. § 0.100(b) (2006). Additionally,
[b]ecause Congress created the Controlled Substances Act (CSA),
Congress can change it. Some possibilities include: passing a bill to
move marijuana into a less restrictive schedule; moving marijuana out
of the CSA entirely; or even replacing the entire CSA with something
completely different. In addition, Congress can remove criminal penalties for the medical use of marijuana regardless of what schedule it
is in.
MARIJUANA POLICY PROJECT, supra note 10, at 4. Finally, “[b]ecause the F[ood] [and]
D[rug] A[dministration] is part of the U.S. Department of Health and Human Services (HHS), the U.S. Secretary of Health and Human Services can declare that marijuana meets sufficient standards of safety and efficacy to warrant rescheduling.” Id.
146
See Alliance for Cannabis Therapeutics v. DEA, 15 F.3d 1131, 1131, 1137 (D.C.
Cir. 1994) (noting that petitions to reschedule marijuana were first filed in 1972 and
had been before the U.S. Court of Appeals for the District of Columbia Circuit on
four prior occasions and upholding the Administrator of the Drug Enforcement
Administration’s denial to reschedule marijuana); Drug Enforcement Administration, Notice of Denial of Petition, 66 Fed. Reg. 20,038 (2001) (denying a petition to
reschedule marijuana based on the scientific and medical findings of the Department of Health and Human Services that marijuana has a high potential for abuse);
see also Gettman v. DEA, 290 F.3d 430 (D.C. Cir. 2002); Krumm v. Holder, No. CIV
08-1056 JB/WDS, 2009 U.S. Dist. LEXIS 52748 (D.N.M. May 27, 2009).
142
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147

law; currently, laws in thirty-one states and the District of Columbia
148
“recognize marijuana’s medicinal value.” Unfortunately, federal restrictions render many of these state laws ineffective and merely sym149
bolic. For instance, a number of state laws allow possession of mari150
Several other states
juana obtained by a physician’s prescription.
and the District of Columbia have re-scheduled marijuana at the state
151
level to recognize the drug’s therapeutic value. These laws do little
to provide individuals with legal access to medical marijuana, however, because physicians are still unable to prescribe and pharmacists
152
are still unable to dispense marijuana without violating federal law.
Seven states have also passed “non-binding resolutions urging the
153
federal government to make marijuana medically available.” While
these resolutions carry little legal weight, they clearly symbolize that
the states recognize the need to provide individuals with access to a
medication that has palliative effects.
In 1996, California was the first state in the nation to pass an effective medical-marijuana law when fifty-six percent of California voters approved ballot Proposition 215, codified as the Compassionate
154
Use Act of 1996.
Twelve states followed California’s lead and

147

MARIJUANA POLICY PROJECT, supra note 10, at 10.
Id. at 1.
149
Id. at 5.
150
See, e.g., ARIZ. REV. STAT. ANN. § 13-3412.01 (LEXIS through 2010 legislation);
CONN. GEN. STAT. ANN. § 21a-246, § 21a-253 (LEXIS through 2010 legislation) (allowing physicians to prescribe marijuana for chemotherapy or glaucoma); LA. REV. STAT.
ANN. § 40:1046 (LEXIS through 2010 Reg. Sess.) (allowing physicians to prescribe
marijuana for glaucoma, cancer chemotherapy and spastic quadriplegia); N.H. REV.
STAT. ANN. § 318-B:9 (2010) (allowing physicians to prescribe marijuana for cancer
chemotherapy and radiology); VA. CODE ANN. § 18.2-251.1 (LEXIS through 2010
Reg. Sess.) (allowing physicians to prescribe marijuana for glaucoma and cancer).
151
See MARIJUANA POLICY PROJECT, supra note 10, at app. A-13–16. In addition to
the District of Columbia, the following states have re-scheduled marijuana at the
state level: Iowa, Tennessee, Arkansas, Maine, New Mexico (only in regard to patients
obtaining marijuana for medicinal purposes under the state Lynn and Erin Compassionate Use Act), and Massachusetts. See id. at app. A.
152
See United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 491 (2001);
see also 21 U.S.C. § 829 (2006) (detailing how drugs classified in Schedules II through
V may be prescribed and dispensed).
153
MARIJUANA POLICY PROJECT, supra note 10, at app. A-20. These states include
California, Michigan, Missouri, New Hampshire, New Mexico, Rhode Island, and
Washington. Id.
154
See NORML, supra note 1; see also CAL. HEALTH & SAFETY CODE § 11362.5 (West
2007). California’s medical marijuana law was amended in 2004 by the Medical Marijuana Program, codified as sections 11362.7–.9.
148

BROWN_FINAL.DOC (DO NOT DELETE)

11/22/2011 9:06 AM

1540

[Vol. 41:1519

SETON HALL LAW REVIEW

155

enacted medical-marijuana legislation between 1998 and 2008.
In
addition to California, medical-marijuana laws in Alaska, Colorado,
Maine, Michigan, Montana, Nevada, Oregon, and Washington were
enacted through the ballot-initiative process or by statewide referen156
dum. In June 2000, Hawaii was the first state to have its state legis157
lature enact its Medical Use of Marijuana Act rather than using a
158
New Mexico, Rhode
ballot initiative as previous states had done.
159
Island, and Vermont soon followed Hawaii’s lead. While each state
law varies in the protection that it provides, each has “removed statelevel criminal penalties for the cultivation, possession, and use of ma-

155

See COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st
Sess.); ALASKA STAT. §§ 17.37.010–.080, 11.71.090 (LexisNexis, LEXIS through 2010
Reg. Sess.); COLO. REV. STAT. §§ 18-18-406.3, 25-1.5-106 (LEXIS through 67th Gen.
Assembly, 1st Sess.); HAW. REV. STAT. §§ 329-121 to -128 (LexisNexis, LEXIS through
2010 Reg. Sess.); ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS through 2009 2d
Reg. Legis. Sess.); MICH. COMP. LAWS ANN. §§ 333.26421 to .26430 (LexisNexis, LEXIS
through P.A. 383 of 2010 Leg. Sess.); MONT. CODE ANN. §§ 50-46-101 to -210 (LexisNexis, LEXIS through 2009 Reg. and Spec. Sess.); NEV. REV. STAT. §§ 453A.010 to 810
(LexisNexis, LEXIS through 2010 Reg. Sess.); N.M. STAT. ANN. §§ 26-2B-1 to -7 (LexisNexis, LEXIS through 2010 2d Spec. Sess.); OR. REV. STAT. §§ 475.300 to .375
(LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-1 to -12 (LEXIS through
Jan. 2010 Legis. Sess.); VT. STAT. ANN. tit. 18, §§ 4472 to 4474(d) (LEXIS through
2010 Sess.); WASH. REV. CODE §§ 69.51A.005 to .902 (LexisNexis, LEXIS through 2010
Reg. and 2d Spec. Sess.). Maryland has also attempted to provide individuals in need
of marijuana for medicinal purposes with some protection from criminal prosecution
by allowing individuals to raise a defense of medical necessity for the use or possession of marijuana during sentencing. See MD. CODE ANN., CRIM. LAW §§ 5-601(c), 619(c) (LexisNexis, LEXIS through 2010 Reg. Sess.) (allowing defendants to raise a
defense of medical necessity for marijuana use or possession and for possession or
use of drug paraphernalia, respectively). If use is proven, an individual is subject to
a fine not to exceed one-hundred dollars but is not be subjected to jail time. See id.
The law fails, however, to provide a defense for cultivation by a medical-marijuana
user or their caregiver. MARIJUANA POLICY PROJECT, supra note 10, at 1. A necessity
defense “gives defendants a chance to prove in court that their violation of the law
was necessary to avert a greater evil.” Id. at app. K-1. In addition, on May 4, 2010,
Washington, D.C. amended its law to allow the medical use of marijuana by patients
suffering from select chronic illnesses. See Ashley Southall, Washington, D.C., Approves
Medical Use of Marijuana, N.Y. TIMES, May 4, 2010, at A17.
156
MARIJUANA POLICY PROJECT, supra note 10, at 1. See also EDDY, supra note 46, at
18. Interestingly, since California enacted the first medical law via ballot initiative in
1996, “voters have approved medical marijuana initiatives in every state where they
have appeared on a ballot with the exception of South Dakota, where a medical marijuana initiative was defeated in 2006 by 52% of the voters.” Id.
157
HAW. REV. STAT. §§ 329-121 to -128 (LexisNexis, LEXIS through 2010 Reg.
Sess.)
158
See NORML, supra note 1; see also MARIJUANA POLICY PROJECT, supra note 10, at
app. A-2.
159
See MARIJUANA POLICY PROJECT, supra note 10, at 1.
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rijuana, if such use has been recommended by a medical doctor.”
Each also provides some type of protection for patients, their caregiv161
ers, and physicians.
C. The Interplay Between State Medical-Marijuana Laws and the CSA
1.

The CSA, Preemption, and States’ Continued
Experimentation

The CSA does not preempt state medical-marijuana laws because
Congress did not intend to occupy the field of drug regulation when
it enacted the CSA, and it sought to leave regulation of the practice
of medicine to the states. Further, thus far, no state law has been
162
found to conflict with the federal law. In short, the state and federal governments simultaneously occupy the field of drug regulation.
Thus, while Congress enacts criminal drug laws as an exercise of its
163
Commerce Clause power, states do so also pursuant to their police
powers to enact legislation for the protection of the health of their
164
citizens.
The Supreme Court has never explicitly ruled that the CSA
165
Additionally, it has never
preempts state medical-marijuana laws.
166
invalidated a state medical-marijuana law. In Gonzales v. Raich, two
California citizens sought “injunctive and declaratory relief prohibiting the enforcement of the CSA” to the extent that it prevented the
patients “from possessing, obtaining, or manufacturing” marijuana
for their personal use under California’s Compassionate Use Act
160

EDDY, supra note 46, at 17.
See id.
162
As stated in a Congressional Research Service report prepared for Congress
that reviewed and analyzed federal and state law policies regarding medical marijuana,
[s]tates can statutorily create a medical use exception for botanical
cannabis and its derivatives under their own, state-level controlled substances laws. At the same time, federal agents can investigate, arrest,
and prosecute medical marijuana patients, caregivers, and providers in
accordance with the federal Controlled Substances Act, even in those
states where medical marijuana programs operate in accordance with
state law.
EDDY, supra note 46, at 4.
163
See supra note 134.
164
See U.S. CONST. amend. X. This power is reserved by the states in the Tenth
Amendment of the United States Constitution, which states, “The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are
reserved to the States respectively, or to the people.” Id.
165
This observation is based on a Lexis search conducted in October 2009.
166
Id.
161
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(CUA).
While the Court held that Congress’s Commerce Clause
authority “includes the power to prohibit the local cultivation and use
of marijuana in compliance with California law,” it did not invalidate
168
the state law.
In fact, Gonzales “was not decided on preemption
169
grounds,” and the Court’s holding “does not mean that the CUA is
170
preempted by federal law.”
Although no lower court has addressed whether the CSA
171
preempts state medical-marijuana laws in their entirety, two courts
have held that specific portions of the CUA were not preempted by
172
the CSA. In City of Garden Grove v. Superior Court, a California appellate court determined that in enacting the CSA, Congress “made it
clear” that it had no intention of preempting the states “on the issue
173
of drug regulation.” The court explained:
Indeed, the CSA explicitly contemplates a role for the States in
regulating controlled substances . . . . It provides: “No provision
of the CSA shall be construed as indicating an intent on the part
of Congress to occupy the field in which that provision operates,
including criminal penalties, to the exclusion of any State law on
the same subject matter which would otherwise be within the authority of the State, unless there is a positive conflict between the
provision . . . and that State law so that the two cannot consistently
174
stand together.”

167

Gonzales v. Raich, 545 U.S. 1, 1 (2005).
See id. at 9.
169
City of Garden Grove v. Superior Ct., 68 Cal. Rptr. 656, 673 (Cal. Ct. App.
2007). The court stated:
The upshot of Raich is that the federal government and its agencies
have the authority to enforce the federal drug laws, even in a state like
California that has sanctioned the use of marijuana for medicinal purposes. However, we do not read Raich as extending beyond this particular point, into the realm of preemption.
Id. at 674.
170
Id. at 674. In its discussion of Gonzales v. Raich, the court specifically stated that
“the high court’s decision did not sound the death knell of the CUA in state court
proceedings.” Id.
171
This observation is based on a Lexis search conducted in October 2009.
172
City of Garden Grove, 68 Cal. Rptr. at 678 (“[F]ederal supremacy principles do
not prohibit the return of marijuana to a qualified user whose possession of the drug
is legally sanctioned under state law.”); County of San Diego v. San Diego NORML,
81 Cal. Rptr. 3d 461, 481–83 (Cal. Ct. App. 2008) (holding that California medicalmarijuana identification card laws are not preempted by the CSA).
173
City of Garden Grove, 157 68 Cal. Rptr. at 675.
174
Id. (citing 21 U.S.C. § 903 (2006)) (internal citations and quotations omitted).
168
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Thus, according to the court, “this express statement by Congress . . .
175
gives the usual assumption against preemption additional force.”
Furthermore, the court stated that “Congress enacted the CSA to
combat recreational drug abuse and curb drug trafficking,” and that
“[i]ts goal was not to regulate the practice of medicine, a task that
176
falls within the traditional powers of the states.”
Ultimately, the
court found that California’s CUA represents “a state statutory
scheme that limits state prosecution for medical marijuana possession
177
but does not limit enforcement of the federal drug laws.” This scenario, according to the court, “simply does not implicate federal su178
premacy concerns.”
After the Supreme Court handed down its ruling in Gonzales, the
Attorneys General from every state that had removed criminal penalties for the medical use of marijuana responded that the decision
179
would have little impact on the viability of the state laws. And since
the ruling, “these laws have continued to provide near total protec180
tion for the sick and dying patients they are intended to protect.”
While the federal government has authority to enforce its laws
throughout the United States, it has no authority to require states to
enforce federal law or to “force states to have laws that are identical
181
to federal law.” State medical-marijuana laws are not preempted by
the CSA because they do not conflict with the federal law, and states
182
may continue to enact medical-marijuana legislation.
2.

The Obama Administration: A New Take on Federal
Drug Law Enforcement

The Obama administration has vowed to refrain from prosecuting individuals who violate federal drug statutes if their actions are
lawful under state law, a move that stands in stark contrast to the policies of both the Clinton and Bush administrations.

175

Id. (internal quotations omitted).
Id. (internal quotations omitted).
177
Id. at 676.
178
Id. at 676–77 (internal citations omitted).
179
See Implications of U.S. Supreme Court Medical Marijuana Ruling, MARIJUANA
POLICY PROJECT, http://www.mpp.org/reports/gonzales-v-raich-the-impact.html (last
visited Oct. 31, 2010).
180
Id.
181
MARIJUANA POLICY PROJECT, supra note 10, at 8.
182
See supra note 162.
176
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Nevertheless, “the federal government still discourages research
183
into the medicinal uses of smoked marijuana.” And federal law enforcement agencies can, and until the election of President Obama
did, continue to enforce federal law against individuals acting under
184
state exceptions for medical marijuana. Some of the first state medical-marijuana laws were passed while President Bill Clinton was in of185
fice.
Under his administration, Attorney General Janet Reno and
Drug Czar Barry McCaffrey “vowed to enforce violations of federal
186
The Bush administration went even
drug laws, namely the CSA.”
further, and federal agents raided medical-marijuana distributors that
violated federal statutes notwithstanding the dispensaries’ com187
pliance with state law.
Even as a presidential candidate, Barack Obama expressed his
opinion that “states should be allowed to make their own rules on
188
medical marijuana.” He has also expressed the opinion that marijuana should be treated as a health issue rather than a criminal jus189
tice issue. President Obama’s position is that “federal resources
190
should not be used to circumvent state laws.”
In February 2009, “in a break from prior policies,” the Obama
administration announced “that federal officials would stop raiding
191
dispensaries of medical marijuana authorized under state law.”
183

Harris, supra note 9, at A1.
See infra notes 186–87 and accompanying text.
185
See NORML, supra note 1. These include laws in California, Alaska, Washington, Maine, Nevada, Colorado and Hawaii. Id.
186
Cathryn L. Blaine, Note, Supreme Court “Just Says No” to Medical Marijuana: A
Look at United States v. Oakland Cannabis Buyers’ Cooperative, 39 HOUS. L. REV.
1195, 1200 (2002) (citing Nicole Dogwill, Note, The Burning Question: How Will the
United States Deal with the Medical-Marijuana Debate, 1998 DET. C.L. REV. 247, 253 n.38
(1998) (discussing the federal government’s stance on Proposition 215 in derogation
of the CSA)).
187
See id. The effect was particularly felt by California as the first of the states to
legalize medical marijuana. Id.
188
Bob Egelko, U.S. to Yield Marijuana Jurisdiction to States, S.F. CHRON., Feb. 27,
2009, at A1.
189
Id.
During one campaign appearance, Obama recalled that his mother
had died of cancer, and said that he saw no difference between doctorprescribed morphine and marijuana as pain relievers. He told an interviewer in March that it was “entirely appropriate” for a state to legalize the medical use of marijuana “with the same controls as other drugs
prescribed by doctors.”
Id.
190
Id.
191
Brian Seltzer, A Popular Plant is Quietly Spreading Across TV Screens, N.Y. TIMES,
Sept. 15, 2009, at C1.
184
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Soon after, U.S. Attorney General Eric Holder reported the Justice
Department’s new policy to only target drug traffickers that use dis192
pensaries as a front. This shift is significant. According to Graham
Boyd, director of the American Civil Liberties Union drug law
project, states were reluctant to effectuate their medical-marijuana
193
laws because of the previous administrations’ policies.
States can
now implement their important health policies without interference
from the federal government.
True to the Obama administration’s earlier representations, on
October 19, 2009, the Department of Justice issued a policy memo to
the U.S. Attorneys in states with medical-marijuana laws advising
them not to allocate federal resources to pursue individuals that are
194
in “clear and unambiguous compliance” with state laws. The memo
does not, however, foreclose the possibility that an individual acting
in compliance with state law could face federal prosecution for violations of federal law, as it appears to leave prosecution to the discre195
tion of the individual U.S. Attorney.
As observed by the New York
Times, “The new stance was hardly an enthusiastic embrace of medical
marijuana, or the laws that allow it in some states, but signaled clearly
that the administration thought there were more important priorities
196
for federal prosecutors.”
192

David Johnston & Neil A. Lewis, Obama Administration to Stop Raids on Medical
Marijuana Dispensers, N.Y. TIMES, Mar. 18, 2009, at A20. But when a federal judge
sentenced the owner of a marijuana dispensary in California to a year in prison in
June 2009, some worried that the Obama administration’s promise was empty. See
Solomon Moore, Prison Term For a Seller of Medical Marijuana, N.Y. TIMES, June 12,
2009, at A18. According to the U.S. District Attorney for the Central District of California, however, the owner had not been acting in compliance with state law, and Justice Department Spokesman Mathew Miller clarified that “as a general rule we are
not prioritizing federal resources to go after individuals or organizations unless there
is a violation of both federal and state law.” Id. Therefore, only if an individual violates the very state law that protects his federally prohibited action does he risk
prosecution.
193
See Johnston & Lewis, supra note 192, at A20.
194
Memorandum on Investigations and Prosecutions in States Authorizing the
Medical Use of Marijuana from David W. Ogden, Deputy Att’y Gen., U.S. Dep’t of
Justice, to Selected United States Att’ys (Oct. 19, 2009), available at
http://www.justice.gov/opa/documents/medical-marijuana.pdf. Noting that “the
Department of Justice is committed to the enforcement of the Controlled Substances
Act in all States” and that “[t]his guidance regarding resource allocation does not
‘legalize’ marijuana or provide a legal defense to a violation of federal law,” the
memo stated that it “is intended solely as a guide to the exercise of investigative and
prosecutorial discretion.” Id.
195
See id.
196
David Stout & Solomon Moore, U.S. Won’t Prosecute in States that Allow Medical
Marijuana, N.Y. TIMES, Oct. 20, 2009, at A1. The article notes that “[s]ome federal
law enforcement officials opposed the administration’s position.” Id.
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State Medical-Marijuana Laws Protect Patients In Need

State laws cannot protect individuals from federal prosecution,
but they can offer considerable protection to patients. State and local law enforcement are responsible for about ninety-nine percent of
197
marijuana-related arrests.
The federal government has not prosecuted anyone living in the first thirteen states with effective medical198
marijuana laws for small amounts of marijuana.
Thus, state lawmakers are in a position to afford patients almost absolute protection
from prosecution related to medical-marijuana use.
IV. THE NEW JERSEY COMPASSIONATE USE MEDICAL MARIJUANA ACT
Until now, existing New Jersey law had failed to distinguish between medical and recreational use, possession, or distribution of
199
marijuana. The NJCMA carves out a narrow exception for the medicinal use of marijuana by individuals who continue to suffer from
the symptoms of debilitating medical conditions despite available
treatment options.
A. An Overview of the NJCMA
1.

Purpose of the Act

The NJCMA seeks to protect from arrest and prosecution seriously ill patients who use medical marijuana to “alleviate suffering
200
from debilitating medical conditions.” The Act also seeks to protect
physicians, caregivers, and authorized producers and distributors of
201
the drug.
This purpose reflects the Legislature’s determination
that compassion dictates a distinction in the law’s treatment of those
202
who use marijuana for medical purposes.
197

MARIJUANA POLICY PROJECT, supra note 10, at app. R-1.
Id.
199
See N.J. STAT. ANN. §§ 2C:35-1 to -29, 2C:36-1 to -10 (West 2010).
200
N.J. STAT. ANN. § 24:6I-2(e) (West 2010).
201
Id.
202
See id. In addition to the legislature’s determination that “[c]ompassion dictates that a distinction be made between medical and non-medical uses of marijuana,” the New Jersey Legislature has found and declared the following:
a. Modern medical research has discovered a beneficial use for marijuana in treating or alleviating the pain or other symptoms associated
with certain debilitating medical conditions, as found by the National
Academy of Sciences’ Institute of Medicine in March 1999;
b. According to the U.S. Sentencing Commission and the Federal
Bureau of Investigation, 99 out of every 100 marijuana arrests in the
country are made under state law, rather than under federal law. Consequently, changing state law will have the practical effect of protecting
198
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Registration, Eligibility, and Physician Requirements

The Act requires the Department of Health and Senior Services
(DHSS) to establish and maintain a confidential registry of qualifying
203
patients and their primary caregivers.
The DHSS must also issue
identification cards to qualifying individuals after a verification pro204
205
cedure. For a patient and his or her primary caregiver to obtain
from arrest the vast majority of seriously ill people who have a medical
need to use marijuana;
c. Although federal law currently prohibits the use of marijuana, the
laws of Alaska, California, Colorado, Hawaii, Maine, Michigan, Montana, Nevada, New Mexico, Oregon, Rhode Island, Vermont, and
Washington permit the use of marijuana for medical purposes, and in
Arizona doctors are permitted to prescribe marijuana. New Jersey joins
this effort for the health and welfare of its citizens;
d. States are not required to enforce federal law or prosecute people
for engaging in activities prohibited by federal law; therefore, compliance with this act does not put the State of New Jersey in violation of
federal law;
§ 24:6I-2.
203
Id. § 24:6I-4(a), (f). All information submitted to the DHSS must be kept confidential and may only be disclosed to select individuals who require the information
for official purposes, including “authorized employees of State or local law enforcement agencies, only as necessary to verify that a person who has engaged in the suspected or alleged medical use of marijuana is lawfully in possession of a registry identification card.” § 24:6I-4(f)(2). Additionally, a qualifying patient’s patient-physician
privilege is not waived by application for, or receipt of, an identification card. §
24:6I-4(g).
204
§ 24:6I-4. If the potential primary caregiver otherwise meets the requirements
of the Act, a primary-caregiver application will be provisionally approved pending the
results of a criminal-background check. § 24:6I-4(b). For a detailed discussion of the
primary-caregiver criminal-background check procedures, see § 24:6I-4(c). “The department shall approve or deny an application or renewal within 30 days of receipt of
the completed application or renewal, and shall issue a registry identification card
within five days of approving the application or renewal.” § 24:6I-4(b). The DHSS
may only deny an application or renewal “if the applicant fails to provide the information required . . . or if the department determines that the information was incorrect or falsified or does not meet the requirements of this act.” Id. Denial of an application or renewal is a final agency decision, subject to judicial review. Id.
205
“Qualifying patient” or “patient” is defined as “a resident of the State who has
been provided with a certification by a physician pursuant to a bona fide physicianpatient relationship.” Id. § 24:6I-3. A “primary caregiver” or “caregiver” is defined as
a resident of the State who: (a) is at least 18 years old; (b) has agreed to
assist with a registered qualifying patient’s medical use of marijuana, is
not currently serving as a primary caregiver for another qualifying patient, and is not the qualifying patient’s physician; (c) has never been
convicted of possession or sale of a controlled dangerous substance,
unless such conviction occurred after the effective date of this act and
was for a violation of federal law related to possession or sale of marijuana that is authorized under this act; (d) has registered with the department pursuant to section 4 of this act, and has satisfied the criminal history record background check requirement of section 4 of this
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206

registry identification cards, which are valid for two years, the patient must submit a signed “certification” from the patient’s physician
that authorizes the patient to apply for registration to use marijuana
207
medicinally. According to the Act, the patient and physician must
be in a “bona fide physician-patient relationship,” which the NJCMA
defines as “a relationship in which the physician has ongoing responsibility for the assessment, care and treatment of a patient’s debilitat208
ing medical condition.” A certification cannot be obtained from a
physician with whom the patient consults solely for the purpose of
209
Only
obtaining authorization for the medical use of marijuana.
physicians licensed to practice medicine in New Jersey may provide
210
certifications.
Additionally, to qualify under the NJCMA, patients and primary
211
Only those patients with a
caregivers must be New Jersey citizens.
“debilitating medical condition” are eligible for protection under the
NJCMA. The Legislature has defined “debilitating medical condition” to mean:
act; and (e) has been designated as primary caregiver on the qualifying
patient’s application or renewal for a registry identification card or in
other written notification to the department.
Id. It is important to note that “no applicant shall be disqualified from serving as a
registered primary caregiver on the basis of any conviction disclosed by a criminal
history record background check . . . if the individual has affirmatively demonstrated
to the commissioner clear and convincing evidence of rehabilitation.” § 24:6I4(c)(5).
206
§ 24:6I-4(a).
207
§ 24:6I-4(a)(1). “Certification” is defined as “a statement signed by a physician
with whom a qualifying patient has a bona fide physician-patient relationship, which
attests to the physician’s authorization for the patient to apply for registration for the
medical use of marijuana.” § 24:6I-3. In addition to a certification, a qualifying patient must submit an application or renewal fee (to be determined on a sliding
scale); the name, address, and birth date of the patient and caregiver (if applicable);
and the name, address and telephone number of the patient’s physician. § 24:6I4(a)(2)–(4).
208
§ 24:6I-3.
209
See id.
210
Id. § 24:6I-5(a). “Physician” is defined as”:
a person licensed to practice medicine and surgery pursuant to Title 45
of the Revised Statutes with whom the patient has a bona fide patient
physician-patient relationship and who is the primary care physician,
hospice physician, or physician responsible for ongoing treatment of
the patient’s debilitating medical condition, provided, however, that
such ongoing treatment shall not be limited to the provision of authorization for a patient to use medical marijuana or consultation solely
for that purposes.
§ 24:6I-3.
211
Id.
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(1) one of the following conditions, if resistant to conventional
medical therapy: seizure disorder, including epilepsy; intractable
skeletal muscular spasticity; or glaucoma; (2) one of the following
conditions, if severe or chronic pain, severe nausea or vomiting,
cachexia, or wasting syndrome results from the condition or
treatment thereof: positive status for human immunodeficiency
virus, acquired immune deficiency syndrome, or cancer; (3)
amyotrophic lateral sclerosis, multiple sclerosis, terminal cancer,
muscular dystrophy, or inflammatory bowl disease, including
Crohn’s disease; (4) terminal illness, if the physician has determined a prognosis of less than 12 months of life; or (5) any other
medical condition or its treatment that is approved by the [De212
partment of Health and Senior Services] by regulation.

Finally, the Act imposes heightened requirements when a qualifying patient is a minor. Specifically, the NJCMA requires written
consent to the medical use of marijuana from a parent or legal guardian and a commitment from the parent to “control the acquisition
and possession of the medical marijuana and any related parapherna213
lia.”
3.

Alternative Treatment Centers and Marijuana Quantity

The NJCMA authorizes patients and caregivers to obtain a patient’s supply of marijuana from a dispensary — an “alternative
214
treatment center.”
A patient may only register at one alternative
215
treatment center at a time.
The Act requires the DHSS to issue
permits to alterative treatment centers and to ensure that the number
of dispensaries throughout the state is sufficient to meet demand, including a minimum of two facilities in northern, central, and south216
ern New Jersey.
The first two permits issued in each of the three
212

Id.
§ 24:6I-5(b) (defining the fiduciary as a “custodial parent, guardian, or person
who has legal custody of the minor”).
214
§ 24:6I-3. The NJCMA defines “medical marijuana alternative treatment center” or “alternative treatment center” as “an organization approved by the [DHSS] to
perform activities necessary to provide registered qualifying patients with usable marijuana and related paraphernalia in accordance with the provisions of [the NJCMA].
This term shall include the organization’s officers, directors, board members, and
employees.” Id.
215
Id. § 24:6I-10(d).
216
Id. § 24:6I-7(a). “The department shall approve or deny an application [for an
alternative treatment center permit] within 60 days of receipt of the completed application.” § 24:6I-§ 7(e). Denial of an application is a final agency decision, subject
to judicial review. Id. A permit to operate as an alternative treatment center may be
suspended or revoked for cause. Id. Such a revocation is also subject to judicial review. Id.
213
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regions will be to non-profit entities; for-profit organizations are eli217
gible to apply thereafter.
Precise permit eligibility requirements
218
await the promulgation of regulations by the DHSS.
To obtain a
permit, however, every individual involved (including employees, officers, and directors of the centers) must undergo a criminal219
background check, for which the applicant must bear the cost. The
DHSS will not issue permits to any person convicted of “a crime involving any controlled dangerous substance or controlled substance
analog” under New Jersey law or any similar state or federal law unless the conviction occurs after the NJCMA became effective and is
for a violation of federal law related to possession or sale of medical
220
marijuana.
The NJCMA authorizes the alternative treatment centers to acquire and maintain a “reasonable” inventory, which the DHSS will determine, “of marijuana seeds or seedlings and paraphernalia” and to
grow, possess, and supply or sell the marijuana and related supplies
221
to registered patients and their caregivers. Centers may charge for
“the reasonable costs associated with marijuana production and dis222
tribution,” whether they operate on a nonprofit or for-profit basis.
To obtain marijuana from a dispensary under the Act, a patient
or caregiver must provide the alternative treatment center with written instructions from the patient’s certifying physician indicating the
amount of marijuana that the patient requires over a thirty-day pe223
riod, which cannot exceed two ounces. A patient or primary caregiver must also present his or her registry identification card, and the

217

§ 24:6I-7(a).
§ 24:6I-7(b).
219
§ 24:6I-7(d)(1).
220
§ 24:6I-7(c) (emphasis added). Note, however, that no alternative treatment
center employee will be disqualified “on the basis of any conviction disclosed” by a
criminal-background check if the individual shows “clear and convincing evidence of
rehabilitation.” See § 24:6I-7(d)(6).
221
§ 24:6I-7(a). The Act establishes that alternative treatment centers may “possess, cultivate, plant, grow, harvest, process, display, manufacture, deliver, transfer,
transport, distribute, supply, sell, or dispense marijuana, or related supplies to qualifying patients or their primary caregivers who are registered with the [DHSS].” Id.
222
§ 24:6I-7(h).
223
Id. § 24:6I-10(a). “A physician may provide a copy of a written instruction by
electronic or other means, as determined by the commissioner, directly to an alternative treatment center on behalf of a registered, qualifying patient.” § 24:6I-10(c).
In the event that no amount is noted, no more than two ounces may be dispensed at
one time. § 24:6I-10(a). In certain limited situations, a physician may issue multiple
instructions at one time, authorizing the patient to receive a total of up to a ninetyday supply. § 24:6I-10(b).
218
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center must verify and log all of the documentation.
The DHSS
must adopt regulations requiring the dispensaries to document care225
fully any pickup or delivery for patients.
4.

Protections Provided by the Act

“Medical use of marijuana” pursuant to the NJCMA means “the
acquisition, possession, transport, or use of marijuana or parapherna226
lia by a registered qualifying patient as authorized by this act.” The
Act does not allow patients to cultivate their own marijuana. It does,
however, provide patients, caregivers, alternative treatment centers,
and physicians acting in conformity with the NJCMA with an affirma227
tive defense to criminal prosecution under New Jersey’s drug laws.
Additionally, such individuals will “not be subject to any civil or administrative penalty, or denied any right or privilege, including, but
not limited to, civil penalty or disciplinary action by a professional licensing board, related to the medical use of marijuana as authorized”
228
by the Act.
The Act provides an explicit exemption from arrest and prosecution—rather than simply an affirmative defense to prosecution—in
two instances. First, individuals who are simply in the vicinity or presence of the authorized medical use of marijuana are not subject to
229
arrest or prosecution. Second, parents or guardians are protected
from arrest or prosecution “for assisting the minor in the medical use
230
of marijuana as authorized” under the NJCMA.
The Act specifically notes that possession of, or application for, a
registry card will not constitute probable cause for law enforcement
224
§ 24:6I-10(c). The Act also notes that written physician instructions become
void if marijuana is not dispensed pursuant to the instructions within one month. Id.
225
§ 24:6I-7(i)(1)–(2). The regulations require written records of “each delivery
of marijuana to, and pickup of marijuana for, a registered qualifying patient, including the date and amount dispensed” be maintained by the alternative treatment centers “to ensure effective documentation of the operations of each alternative treatment center.” § 24:6I-7(i)(1).
226
Id. § 24:6I-3
227
Id. § 24:6I-6(b). The Act provides this affirmative defense to prosecution under Chapters 35 and 36 of New Jersey’s Code of Criminal Justice by amending N.J.
STAT. ANN. § 2C:35-18 so that a qualifying patient, primary caregiver, physician, alternative treatment center—or any other person acting in accordance with the provisions of the act—may raise an affirmative defense if he or she is in compliance with
the NJCMA. See § 2C:35-18. A defendant claiming protection under the Act must
prove the affirmative defense by a preponderance of the evidence. Id. § 24:6I-12(a).
228
§ 24:6I-6(b).
229
§ 24:6I-6(e).
230
§ 24:6I-6(f).
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to search one’s person or property.
Law enforcement is also not
permitted to destroy marijuana possessed lawfully under the NJCMA,
provided that the patient or primary caregiver is in possession of a
registry identification card and no more marijuana than is statutorily
232
allowed.
Finally, the Act provides that the State and its employees and
agents shall be exempted from liability “for any deleterious out233
comes” that may result from a patient’s marijuana use.
The Act
does not explicitly provide the same protections for physicians or alternative treatment centers.
5.

The NJCMA’s Sensible Limitations

The Act places sensible limits on when and where a patient may
engage in the medical use of marijuana. For instance, patients may
not operate a vehicle or heavy equipment “while under the influence
234
of marijuana.”
This restriction comports with medical evidence
suggesting that marijuana may impair motor skills, attention, and
235
reaction time.
The NJCMA also restricts where a patient may
smoke. For instance, patients are prohibited from smoking marijuana on public transportation, in private cars while in operation, on
school grounds, in public parks, beaches and recreational areas, in
correctional facilities, and wherever New Jersey law otherwise prohi236
bits smoking generally.
The Act seeks to ensure that a patient’s
medical-marijuana use will not affect other people in public places.
The NJCMA does not require governmental or private insurers
to reimburse patients for medical-marijuana costs, and it does not re237
quire employers to accommodate marijuana use in any workplace.
The Act is silent, however, as to whether employers can fire or refuse
to hire an individual for failing a drug test because of lawful marijuana use outside the workplace. This has been an issue in other states,
including Oregon, and courts have generally held that employers

231

§ 24:6I-6(c).
§ 24:6I-6(d).
233
Id. § 24:6I-15. The Act also protects from liability for “any actions taken in accordance with” the NJCMA. Id.
234
Id. § 24:6I-8(a).
235
AM. COLL. OF PHYSICIANS, supra note 56, at 6.
236
§ 24:6I-8(b).
237
Id. § 24:6I-14. Rhode Island is the only state that “specifically protects workers
from being fired for their medical use of the drug.” Courtney Rubin, Medical Marijuana Laws Leave Employers Dazed and Confused, INC.COM (Feb. 12, 2010),
http://www.inc.com/news/articles/2010/02/marijuana-law-confusing.html.
232
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need not accommodate medical-marijuana use outside of the
238
workplace.
The Act also makes it a crime to transfer or falsify registration
239
cards or to present a false or altered card to law enforcement. This
deters abuse of the registration system.
6.

Regulation, Reporting Requirements, and
Implementation

The NJCMA requires the Commissioner of the DHSS, in consultation with the Department of Law and Public Safety, to “promulgate
240
The Act
rules and regulations to effectuate” the Act’s purposes.
explicitly requires the DHSS to adopt regulations to “monitor, oversee, and investigate all activities performed by an alternative treat241
ment center.”
The Commissioner must also establish standards to
“ensure adequate security of all facilities 24 hours per day, including
production and retail locations, and security of all delivery methods
242
to registered qualifying patients.”
The NJCMA also includes reasonable reporting requirements to
detect abuse and ensure that the Act achieves its goal. It mandates
that both alternative-treatment centers and participating physicians
furnish to the Director of the Division of Consumer Affairs in the
Department of Law and Public Safety information for inclusion in a

238
See, e.g., Washburn v. Columbia Forest Prods. Inc., 104 P.3d 609, 616 (Or. Ct.
App. 2005) (reversing a grant of summary judgment, the court stated that “concern
about employees coming to work under the influence of marijuana might provide . .
. justification for not accommodating [medical-marijuana use outside of the
workplace]”).
239
See N.J. STAT. ANN. § 24:6I-9 (West 2010). These criminal penalties supplement
existing criminal law and are not intended to “limit prosecution or conviction for any
other offense.” Id.
240
Id. § 24:6I-16(a). The Commissioner must also adopt interim regulations to
implement the provisions of the Act within ninety days of the Act taking effect. §
24:6I-16(b). The regulations will be effective until the adoption of final rules, and
regulations may be amended as necessary. Id. In terms of financing, the Act would
allow the Commissioner of the DHSS to accept from any source grants or contributions to carry out the purpose of the Act. Id. § 24:6I-11(a). Additionally, any fees collected pursuant to the Act, including qualifying patient or alternative treatment center application fees, “shall be used to offset the cost of the department’s
administration of the provisions of” the Act. § 24:6I-11(b).
241
Id. § 24:6I-7(i)(2).
242
§ 24:6I-7(i)(3).
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monitoring system, as is required with other controlled dangerous
243
substances under New Jersey law.
The Commissioner of the DHSS must inform the Governor and
the Legislature of all actions that the Agency has taken to implement
244
the Act’s mandates within one year of the Act’s effective date.
In
addition, the Commissioner has extensive annual reporting requirements, including: the number of registry applications, the number of
registered patients and primary caregivers, the number of revoked
cards, the nature of the reported conditions, the number of permits
issued to and revoked from alternative treatment centers, and the
245
number of participating physicians. Every two years, starting no later than two years after the Act’s effective date, the Commissioner
must also report whether the state’s total number of alternative
treatment centers and the maximum amount of marijuana allowed
pursuant to the Act are sufficient to meet patients’ needs, in addition
to reporting whether the alternative treatment centers are charging
246
excessive prices. These reporting requirements will allow the state
to assess the law’s effectiveness and make any necessary adjustments
to it.
Finally, while the NJCMA took effect on October 1, 2010, the
DHSS Commissioner and the Director of the Division of Consumer
Affairs were authorized to take administrative action in advance to ef247
fectuate the Act. This timing provision was intended to allow state
officials to establish a proper infrastructure before the Act was implemented.
B. Critique of the Legislation
Overall, the NJCMA is among the most restrictive medicalmarijuana laws in the nation because it provides considerable safeguards against abuse and diversion. The Act does not conflict with
federal law because it requires physicians to provide certifications ra-

243

N.J. STAT. ANN. § 45:1-45.1(a); Id. § 45:1-45. The information provided will be
cross-referenced with the electronic system for monitoring controlled dangerous
substances currently in existence in New Jersey. See § 45:1-45.1(a).
244
Id. § 24:6I-12(a)(1).
245
Id.
246
§ 24:6I-12(c).
247
S. 2105, 214th Leg., 2010–2011 Sess. (N.J. 2010). It is important to note that
while the Act was intended to take effect six months after enactment, the legislature
approved an amendment to the Act in June 2010 that extended the effective date.
See id.
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248

ther than prescriptions, and it does not remove criminal penalties
for violations of federal drug law. More importantly, the NJCMA ensures that citizens of New Jersey who suffer from debilitating medical
conditions will have legal access to medical marijuana that is highly
regulated and extensively overseen by the DHSS. Despite some room
for improvement, New Jersey legislators have crafted a law that has
the potential to both achieve its purpose of providing medical marijuana to patients in need and prevent exploitation of the system.
1.

Strengths of the NJCMA

The registration requirement and issuance of identification
cards are positive aspects of the Act and consistent with the policies of
249
most other states with effective medical-marijuana legislation.
These safeguards allow New Jersey to track who has authorization to
use medical marijuana or to assist in such use. This, in turn, allows
law enforcement to know if an individual is operating outside of the
NJCMA. The importance of such requirements is evident from examining states that have failed to implement them. In Washington,
for example, the lack of a patient registry makes it difficult to track
250
the number of patients using marijuana legally.
Additionally, because the state does not issue identification cards, law enforcement
has had difficulty distinguishing between lawful and unlawful mariju251
ana users. “As a result, law enforcement varies throughout the state
248
Compare N.J. STAT. ANN. § 24:6I-5 (West 2010), with 21 U.S.C. §§ 812, 829
(2006) (detailing how drugs classified in Schedules II through V may be prescribed
and dispensed).
249
See, e.g., COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st
Sess.); ALASKA STAT. §§ 17.37.030, .080 (LexisNexis, LEXIS through 2010 Reg. Sess.);
HAW. REV. STAT. § 329-123 (LexisNexis, LEXIS through 2010 Reg. Sess.); MICH. COMP.
LAWS ANN. § 333.26424 (LexisNexis, LEXIS through P.A. 383 of 2010 Leg. Sess.);
MONT. CODE ANN. § 50-46-201 (LexisNexis, LEXIS through 2009 Reg. and Spec.
Sess.); NEV. REV. STAT. § 453A.200 (LexisNexis, LEXIS through 2010 Reg. Sess.); N.M.
STAT. ANN. § 26-2B-4 (LexisNexis, LEXIS through 2010 2d Spec. Sess.); OR. REV. STAT.
§ 475.309 (LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-4 (2010); VT.
STAT. ANN. tit. 18, § 4474(b) (LEXIS through Jan. 2010 Legis. Sess.). Notably, however, some states that have registration programs allow patients and (or) caregivers to
raise an affirmative defense to prosecution if they are not registered but otherwise in
compliance with the requirements of the statute. E.g., COLO. CONST. Art. XVIII §
14LEXIS through 67th Gen. Assembly, 1st Sess.); MICH. COMP. LAWS ANN. § 333.26428
(LexisNexis, LEXIS through P.A. 383 of 2010 Leg. Sess.); MONT. CODE ANN. § 50-46206 (LexisNexis, LEXIS through 2009 Reg. and Spec. Sess.); NEV. REV. STAT. §
453A.310 (LexisNexis, LEXIS through 2010 Reg. Sess.); OR. REV. STAT. § 475.319
(LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-8 (LEXIS through Jan.
2010 Legis. Sess.).
250
MARIJUANA POLICY PROJECT, supra note 10, at app. F-14.
251
See id.

BROWN_FINAL.DOC (DO NOT DELETE)

11/22/2011 9:06 AM

1556

[Vol. 41:1519

SETON HALL LAW REVIEW

and several patients have been arrested or had their marijuana seized
because police and patients have differing interpretations of the
252
253
law.” Maine has experienced similar problems.
The Act also requires that the physician providing the patient’s
certification be responsible for the ongoing treatment of the condi254
tion for which the patient requires the drug.
Thus, a patient may
not obtain a certification from a physician with whom the patient
255
This
consulted solely to obtain authorization to use marijuana.
provision seeks to prevent abuse by reducing the likelihood that patients will obtain a certification when no real need exists. In California, for instance, patients are only required to obtain an oral recom256
mendation from a physician to obtain medical marijuana.
The
problem, as evidence suggests, is that some physicians freely provide
recommendations for medical marijuana—some even advertise their
257
willingness to do so.
Another positive aspect of the NJCMA is that it allows patients to
designate a primary caregiver to assist them in their use or acquisition

252
Id. at app. F-15. In addition to proof of identity, patients in Washington are
required to have “valid documentation,” which is defined as “a statement signed by a
qualifying patient’s physician, or a copy of the qualifying patient’s pertinent medical
records, which states that in the physician’s professional opinion, the patient may
benefit from the medical use of marijuana.” WASH. REV. CODE § 69.51A.010(5)(a),
(b)(LexisNexis, LEXIS through 2010 Reg. and 2d Spec. Sess.). Law enforcement has
had difficulty determining what constitutes an appropriate doctor’s recommendation
when confronting an individual claiming to be an authorized user. MARIJUANA
POLICY PROJECT, supra note 10, at app. F-15.
253
See MARIJUANA POLICY PROJECT, supra note 10, at app. F-1, F-10. State authorities
in Maine cannot track the number of patients legally using marijuana and law enforcement cannot discern lawful marijuana users from unlawful ones. Id. In addition, California has established a voluntary patient registry. See CAL. HEALTH & SAFETY
CODE § 11362.71 (Deering, LEXIS through 2010 legislation and 2011 Supp.). Those
who register are exempt from arrest and prosecution, while those who do not are exempted only from arrest. See id.
254
N.J. STAT. ANN. § 24:6I-3 (West 2010).
255
Id.
256
See CAL. HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011 Supp.). Notably, however, for citizens of California to obtain a voluntary registration card that provides them with an exemption from arrest, heightened requirements must be satisfied. See id. § 11362.715 (defining what is required
to obtain an identification card, including written documentation from an “attending physician”); id. § 11362.7 (defining “attending physician” as, inter alia, “an individual . . . who has taken responsibility for an aspect of the medical care, treatment,
diagnosis, counseling, or referral of a patient and who has conducted a medical examination of hat patient”).
257
See Roger Parloff, How Marijuana Became Legal, FORTUNE (Sept. 18, 2009),
http://money.cnn.com/2009/09/11/magazines/fortune/medical_marijuana_legali
zing.fortune/
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258

of medical marijuana and provides the caregiver with the same protection from criminal liability as it does patients, physicians, and dis259
pensary operators. This is consistent with each of the thirteen medical-marijuana laws currently in effect, which provide virtually the
260
same protections to caregivers or “designated providers” that they
261
do to patients. Considering that patients in need of marijuana are
suffering from debilitating illnesses that could likely require caregiver
assistance, caregiver protection is an important aspect of effective
medical-marijuana legislation. One potential deficiency in the New
262
Jersey law is that a caregiver may only assist one patient at a time.
The requirement is arbitrary and a potential barrier to access for patients with no family or friends to serve as a caregiver. The Act
should permit professional caregivers to provide assistance to more
than one patient at a time.
Another positive aspect of the New Jersey law is that it allows pa263
tients to obtain marijuana from dispensaries. The establishment of
state-licensed alternative treatment centers under the Act will make
New Jersey the fourth state, in addition to New Mexico, Rhode Island,
264
and Maine, to establish such strictly regulated medical marijuana
258

N.J. STAT. ANN. § 24:6I-3 (West 2010).
See supra note 227.
260
See, e.g., WASH. REV. CODE § 69.51A.010 )(LexisNexis, LEXIS through 2010 Reg.
and 2d Spec. Sess.).
261
COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st Sess.);
ALASKA STAT. §§ 17.37.030, 11.71.090 (LexisNexis, LEXIS through 2010 Reg. Sess.);
CAL. HEALTH & SAFETY CODE § 11362.5, 11362.71(e) (Deering, LEXIS through 2010
legislation and 2011 Supp.); COLO. REV. STAT. § 18-18-406.3 (LEXIS through 67th
Gen. Assembly, 1st Sess.); HAW. REV. STAT. § 329-125 (LexisNexis, LEXIS through
2010 Reg. Sess.); ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS through 2009 2d
Reg. Legis. Sess.); MICH. COMP. LAWS ANN. §§ 333.26424, .26428 (LexisNexis, LEXIS
through P.A. 383 of 2010 Leg. Sess.); MONT. CODE ANN. §§ 50-46-201, -206 (LexisNexis, LEXIS through 2009 Reg. and Spec. Sess.); NEV. REV. STAT. §§ 453A.200 (LexisNexis, LEXIS through 2010 Reg. Sess.); N.M. STAT. ANN. § 26-2B-4 (LexisNexis, LEXIS
through 2010 2d Spec. Sess.); OR. REV. STAT. §§ 475.309 (LEXIS through 2009 Legis.
Sess.); R.I. GEN. LAWS § 21-28.6-4 to -8 (LEXIS through Jan. 2010 Legis. Sess.); VT.
STAT. ANN. tit. 18, § 4474(b) (LEXIS through 2010 Sess.); WASH. REV. CODE §§
69.51A.005 (LexisNexis, LEXIS through 2010 Reg. and 2d Spec. Sess.).
262
N.J. STAT. ANN. § 24:6I-3 (West 2010).
263
Id. § 24:6I-7(a).
264
See Abby Goodnough, A Setback in Maine for Gay Marriage, but Medical Marijuana
TIMES
(Nov.
4,
2009),
Law
Expands,
N.Y.
http://www.nytimes.com/2009/11/05/us/politics/05maine.html. In contrast to the
other three states, which each allow only non-profit dispensaries, only the first two alternative treatment centers in each of the northern, central and southern regions of
New Jersey must function as non-profit entities under the NJCMA. § 24:6I-7(a). Any
other alternative treatment center approved by the DHSS may operate as either a
non-profit or for-profit entity. Id.
259
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dispensaries. California, in contrast, does not require dispensaries
to obtain licenses, which has resulted in a proliferation of dispensaries and the alleged sale of marijuana to people who should not qual266
ify to receive the drug. Opponents of the NJCMA cite California as
evidence that dispensaries cause serious abuse and diversion prob267
lems.
The cannabis outlets in California, however, are not state268
licensed and are thus not regulated adequately by the state.
In comparison, the NJCMA requires licensing, regulation, and
extensive oversight of all alternative treatment centers throughout
269
the state.
This will ensure that New Jersey citizens have safe but
controlled access to marijuana. As discussed, the Act requires pros270
pective dispensary operators to obtain a permit from the DHSS. To
do so, anyone involved in the operations of the center must undergo
271
a criminal-background check. No one convicted of a crime involving any controlled dangerous substance under New Jersey law or a
272
similar state or federal law would qualify for a permit. If, however,
the conviction occurred after the NJCMA became effective and was
for a violation of federal law related to medical marijuana, the person
273
would qualify.
Additionally, unlike California dispensaries, New Jersey dispensaries are authorized to distribute marijuana only to patients or care-

265

Goodnough, supra note 264. California also allows marijuana cooperatives under its medical marijuana laws, and Oregon allows for marijuana grow sites. See CAL.
HEALTH & SAFETY CODE § 11362.775 (Deering, LEXIS through 2010 legislation and
2011 Supp.)(allowing collective or cooperative cultivation of marijuana by qualified
persons); OR. REV. STAT. §§ 475.304 to .375 (LEXIS through 2009 Legis.
Sess.)(providing for the regulation of marijuana grow sites where individuals are allowed to grow marijuana for qualified patients).
266
Reports vary but they generally indicate that California has more than 700
medical marijuana dispensaries throughout the state. See, e.g., Parloff, supra note
257.
267
See, e.g., Mary Pat Angelini, New Jersey Teens Will Do More Drugs Because We Lega(Jan.
26,
2010),
lized
Medical
Marijuana,
NEWJERSEYNEWSROOM.COM
http://www.newjerseynewsroom.com/commentary/new-jersey-teens-will-do-moredrugs-because-we-legalized-medical-marijuana.
268
See Clark Canfield, Maine Becomes 5th State to Allow Pot Dispensaries, ASSOCIATED
PRESS, Nov. 5, 2009, available at http://abcnews.go.com/US/wireStory?id=8997909.
269
See N.J. STAT. ANN. § 24:6I-7 (West 2010).
270
§ 24:6I-7(a).
271
§ 24:6I-7(d).
272
§ 24:6I-7(c). Note, however, that no alternative treatment center employee will
be disqualified “on the basis of any conviction disclosed” by a criminal background
check if the individual shows clear and convincing evidence of rehabilitation.” See §
24:6I-7(d).
273
§ 24:6I-7(c) (emphasis added).

BROWN_FINAL.DOC (DO NOT DELETE)

2011]

11/22/2011 9:06 AM

COMMENT

1559

givers who present both a registry identification card and written phy274
sician instructions that authorize a specific amount to be dispensed.
The NJCMA also requires centers to verify and log the patient’s do275
cumentation, which ensures that the DHSS will be able to monitor
treatment centers’ distribution. The added requirement that physicians must report issuing patient certifications and written instructions to the Department of Law and Public Safety, and the inclusion
276
of this information in a monitoring system, will also help to prevent
abuse and diversion. Furthermore, the Act allows patients to register
277
at only one alternative treatment center at a time. This ensures that
patients cannot circumvent the quantity limits imposed by the Act.
The requirement that a physician provide written quantity instructions not only eliminates discretion on the part of the alternative
treatment centers but also adds legitimacy to the proposed Act.
While a physician cannot prescribe marijuana under federal law be278
cause it is a Schedule I substance, the written instruction requirement brings the process as close to prescribing as possible without violating federal law.
The Act also requires the state to extensively regulate alternative
treatment centers. For instance, the DHSS would be responsible for
establishing regulations for the approval and monitoring of all alter279
native treatment center activities. It would also set standards to en280
sure the security of the centers.
This addresses opponents’ concerns about “peripheral crime around these centers in the states that
281
have them.”
Another positive aspect of the Act is that it clearly defines the
maximum quantity of marijuana that patients are allowed to acquire
282
at any given time.
When California and Washington first enacted
their medical-marijuana laws, neither state’s law adequately defined
274

Id. § 24:6I-10(c).
Id.
276
§ 24:6I-10(a).
277
§ 24:6I-10(d).
278
See 21 U.S.C. §§ 812, 829 (2006) (detailing how drugs classified in Schedules II
through V may be prescribed and dispensed).
279
N.J. STAT. ANN. § 24:6I-7(b), (i) (West 2010).
280
§ 24:6I-7(i).
281
See A804/S119 Passes Assembly Health & Senior Services Committee, COAL. FOR
MEDICAL MARIJUANA – N.J., http://www.cmmnj.org/id13.htm (last visited Mar. 27,
2011). During the full General Assembly Health and Senior Services Committee
Meeting on June 4, 2009, a representative from the New Jersey Fraternal Order of
Police questioned how security would be handled at the centers. See id.
282
§ 24:6I-10(a).
275
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the allowable quantity.
This resulted in confusion among law enforcement that, at least in California, “sometimes err[ed] on the side
of prosecuting—or at least hassling—patients if the quantity
284
seem[ed] too large.” On the other hand, while it has the potential
to prevent abuse and diversion, New Jersey’s limit, two ounces per
285
thirty days, appears to be somewhat arbitrary and restrictive. Without knowing the quality of the marijuana, arguing that the amount is
inadequate is impossible. But the limit is certainly among the smallest quantities allowed in any of the states that have legalized medical
286
marijuana.
In addition, some state medical-marijuana laws have
283

California’s Compassionate Use Act did not define quantity at all. See CAL.
HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011
Supp.). In contrast, Washington’s Medical Use of Marijuana Act defined the quantity as “no more marijuana than is necessary for the patient’s personal, medical use,
not exceeding the amount necessary for a sixty-day supply,” but it failed to define sixty-day supply. See WASH. REV. CODE § 69.51A.040 (LexisNexis, LEXIS through 2010
Reg. and 2d Spec. Sess.). The “sixty-day supply” language was subsequently defined
in October of 2008 as 24 ounces and 15 plants. See WASH. ADMIN. CODE § 246-75-010
(LEXIS through Aug. 2011); Medical Marijuana, WASH. STATE DEP’T OF HEALTH,
http://www.doh.wa.gov/hsqa/medical-marijuana/(last
visited
Oct.
1,
2011)[hereinafter Medical Marijuana Wash. State Dept.]; see also WASH. REV. CODE §
69.51A.080 (LexisNexis, LEXIS through 2010 Reg. and 2d Spec. Sess.) (defining sixty-day supply, but noting that this amount is presumptive and can “be overcome with
evidence of a qualifying patient’s necessary medical use”).
284
See MARIJUANA POLICY PROJECT, supra note 10, at app. F-15.
285
N.J. STAT. ANN. § 24:6I-10(a) (West 2010).
286
See, e.g., COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st
Sess.)(allowing a patient to possess no more than two ounces of usable marijuana
and six marijuana plants, but noting that an affirmative defense can be raised if the
patient or caregiver is in possession of more when it is medically necessary); ALASKA
STAT. § 17.37.040 (LexisNexis, LEXIS through 2010 Reg. Sess.) (“[A] patient, primary
caregiver, or alternative caregiver may not . . . possess in the aggregate more than
once ounce of marijuana in usable form; and six marijuana plants.”); CAL. HEALTH &
SAFETY CODE § 11362.77 (Deering, LEXIS through 2010 legislation and 2011
Supp.)(allowing a qualified patient or primary caregiver to possess “no more than
eight ounces of dried marijuana” and “no more than six mature of twelve immature
plants” per patient, but also noting that this amount can be overcome if a doctor determines that the amount does not meet the patient’s need, and that counties or cities may increase the amount as they see fit); HAW. REV. STAT. § 329-121 (LexisNexis,
LEXIS through 2010 Reg. Sess.) (stating that a qualifying patient and his or her caregiver may possess jointly an “adequate supply” of marijuana, not to exceed three mature plants, four immature plants, and one ounce of usable marijuana per each mature plant); ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS through 2009 2d Reg.
Legis. Sess.) (defining “usable amount of marijuana for medical use” as “2 1/2
ounces or less of harvested marijuana . . . and a total of 6 plants”); MICH. COMP. LAWS
ANN. § 333.26424 (LexisNexis, LEXIS through P.A. 383 of 2010 Leg. Sess.)(stating
that a patient may possess no more than 2.5 usable ounces of marijuana and, if they
have not designated a caregiver to grow for them, twelve plants kept in an enclosed,
locked facility, and stating that at primary caregiver may possess no more than 2.5
ounces of usable marijuana for each patient he cares for and no more than twelve
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explicit quantity limits but allow a patient to raise an affirmative defense at trial for possession of an unlawful quantity if the patient is
287
otherwise in compliance with the statute.
The Legislature should
consider amending the NJCMA to include a similar provision; it
could include an upper limit on the allowable amount to determine a
fixed range it considers reasonable.
2.

Deficiencies, Unaddressed
Improvements

Issues,

and

Suggested

Although the Act’s restrictiveness will help avoid abuse and diversion, certain—and arguably over-restrictive—portions of the
NJCMA threaten to prevent it from achieving its purpose by limiting
the protections provided by the law and creating barriers to access.
plants to be kept in an enclosed, locked facility); MONT. CODE ANN. § 50-46-201 (LexisNexis, LEXIS through 2009 Reg. and Spec. Sess.) (stating that a patient and his caregiver may not posses more than one ounce of usable marijuana and six marijuana
plants each); NEV. REV. STAT. § 453A.200 (LexisNexis, LEXIS through 2010 Reg. Sess.)
(stating that a patient or primary caregiver “may collectively possess, deliver or produce” no more than “one ounce of usable marijuana; three mature plants; and four
immature plants,” but also providing an affirmative defense if patients or their caregivers are in possession of a larger amount); N.M. STAT. ANN. §§ 26-2B-3 (LexisNexis,
LEXIS through 2010 2d Spec. Sess.)(defining adequate supply to as “no more than
reasonably necessary to ensure the uninterrupted availability of cannabis for a period
of three months”); OR. REV. STAT. § 475.320 (LEXIS through 2009 Legis. Sess.) (“[A]
registry identification cardholder or designated primary caregiver may possess up to
six mature marijuana plants and 24 ounces of usable marijuana.”); R.I. GEN. LAWS §
21-28.6-4 (LEXIS through Jan. 2010 Legis. Sess.)(stating that a patient may possess no
more than twelve marijuana plants and two and a half ounces of usable marijuana
and that a caregiver may not possess more than that amount for each patient she
aids); VT. STAT. ANN. tit. 18, § 4472 (LEXIS through 2010 Sess.)(stating that a registered patient and their caregiver may collectively possess “no more than two mature
marijuana plants, seven immature plants, and two ounces of usable marijuana”);
WASH. ADMIN. CODE 246-75-010 (LexisNexis, LEXIS through 2010 Reg. and 2d Spec.
Sess.) (defining sixty-day supply, and noting that this amount can be overcome based
on the need of the patient); Medical Marijuana Wash. State Dept., supra note 283 (defining “sixty-day supply” in October of 2008 as 24 ounces and 15 plants).
It appears that currently in New Mexico patients/primary caregivers can possess
six ounces of usable marijuana, and can either obtain marijuana through licensed
non-profits (“cannabis production facilities”) within the state or apply to produce
their own marijuana (four mature plants and twelve seedlings). See Medical Cannabis
DEP’T
OF
HEALTH,
Program
Frequently
Asked
Questions,
N.M.
http://nmhealth.org/idb/mcp_faq.shtml (last visited Mar. 27, 2011). The nonprofits may be in possession of up to ninety-five mature plants and seedlings, as well
as usable inventory to service the patients in the program. See id.
287
See, e.g., NEV. REV. STAT. § 453A.310 (LexisNexis, LEXIS through 2010 Reg.
Sess.)(providing an affirmative defense to patients and primary caregivers in possession of more than the allowed quantity of marijuana if that person “proves by a preponderance of the evidence that the greater amount is medically necessary as determined by the person’s (or assisted person’s) attending physician to mitigate the
symptoms or effects of the person’s chronic or debilitating medical condition.”).
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One significant deficiency of the NJCMA is that it exempts patients, primary caregivers, dispensary operators, and physicians from
criminal liability but not from arrest or prosecution; the Act allows
288
them only to raise an affirmative defense to prosecution. Only parents or guardians assisting minors under the Act receive exemption
289
from arrest or prosecution.
This appears to be inconsistent with
the Act’s stated purpose of protecting patients, caregivers, physicians,
290
and dispensary operators from arrest and prosecution.
The distinction is that while the Act protects these individuals from criminal liability if they prove compliance with the Act by a preponderance of
291
the evidence, they would not necessarily escape the trauma of arrest
and prosecution. The other thirteen states vary in the protection that
they provide from criminal liability. California, for instance, provides
an exemption from prosecution to unregistered patients who comply
with its medical-marijuana laws, but an exemption from both arrest
292
and prosecution to registered patients.
Vermont provides an exemption from arrest and prosecution to all registered patients in
293
compliance with the statute. Montana provides an exemption from
arrest and prosecution if a patient is registered, but it also allows unregistered patients to raise an affirmative defense if they are other294
wise in compliance with the law. Alaska’s law, like the NJCMA, only
295
provides patients with an affirmative defense.
The Legislature should amend the NJCMA to explicitly exempt
the aforementioned individuals from arrest and prosecution when
they act in compliance with the law. No reason exists for patients authorized to use marijuana for the treatment of a debilitating medical
condition to go through the process of arrest and prosecution if they
are in compliance with the law. Physicians may be reluctant to provide patients with certifications if they are not exempted from arrest
and prosecution. Likewise, caregivers might be hesitant to provide
assistance to patients. These results are inconsistent with the Act’s
purpose.

288

See supra note 227.
N.J. STAT. ANN. § 24:6I-6(f) (West 2011).
290
Id. § 24:6I-2(e) (emphasis added).
291
See supra note 227.
292
CAL. HEALTH & SAFETY CODE §§ 11362.5, 11362.71(e)–(f) (Deering, LEXIS
through 2010 legislation and 2011 Supp.).
293
VT. STAT. ANN. tit. 18, § 4474b(a) (LEXIS through 2010 Sess.).
294
MONT. CODE ANN. §§ 50-46-201, -206 (LexisNexis, LEXIS through 2009 Reg.
and Spec. Sess.).
295
ALASKA STAT. § 17.37.030 (LexisNexis, LEXIS through 2010 Reg. Sess.).
289
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In lieu of, or in addition to amending the Act, the DHSS or the
Attorney General should issue guidance to state and local law enforcement directing them to use discretion in investigating a claim of
medical-marijuana use and encouraging arrest only if the patient, caregiver, or operator is not in possession of a valid ID card or permit
or if they are unable to verify the patient’s lawful registration. Cali296
fornia has done this.
The Legislature should also consider allowing patients who are
unregistered but otherwise in compliance with the law to raise an af297
firmative defense at trial, which Montana has done. This would certainly require a balancing of the risks and benefits. As the law currently stands, because all patients are required to register with the
298
DHSS and because of the extensive tracking of patient certifications
and physician instructions by the DHSS and the Department of Law
299
and Public Safety, the state will be able to track exactly who is receiving medical marijuana, how much they are receiving, who is recommending it, and who is distributing it. This will help prevent
abuse and diversion. But if registering deters patients from obtaining
the drug, perhaps providing an affirmative defense to prosecution to
those not registered but otherwise in compliance would ensure that
the Legislature is achieving its stated purpose of protecting “patients
who use marijuana to alleviate suffering from debilitating medical
300
conditions.”
Another arguable deficiency of the NJCMA is that it fails to cover
serious health ailments. The definition of “debilitating medical condition” excludes severe or chronic pain (except pain caused by
301
HIV/AIDS or cancer) as a qualifying condition. “Nearly half of all
current physician recommendations for marijuana therapy are for
chronic pain,” with chronic pain affecting about one in five Ameri-

296

OFFICE OF THE ATTORNEY GEN., CALIF. DEP’T OF JUSTICE, GUIDELINES FOR THE
SECURITY AND NON-DIVERSION OF MARIJUANA GROWN FOR MEDICAL USE (Aug. 2008),
available
at
http://ag.ca.gov/cms_attachments/press/pdfs/n1601_medicalmarijuanaguidelines.
pdf.
297
See MONT. CODE ANN. §§ 50-46-201, -206 (LexisNexis, LEXIS through 2009 Reg.
and Spec. Sess.).
298
N.J. STAT. ANN. § 24:6I-4(a) (West 2010).
299
Id. § 24:6I-11.
300
Id. § 24:6I-2(e).
301
See id. § 24:6I-3.
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302

cans. The Coalition for Medical Marijuana New Jersey has criticized
the law’s failure to help so many people suffering from severe or
303
chronic pain. Nearly every other state medical-marijuana law allows
304
patients suffering from chronic or severe pain to obtain the drug.
But the NJCMA does appear to provide marijuana to patients
with some of the most debilitating illnesses, including any terminal
305
illness that results in a prognosis of less than one year to live. The
Act’s restrictive definition prevents abuse and helps ensure that only
patients with legitimate needs obtain marijuana. It stands in stark
contrast to California’s Compassionate Use Act, which includes an
expansive catchall provision; in California, qualifying conditions in306
clude “any other illness for which marijuana provides relief.” While
initially restrictive, New Jersey’s law allows the DHSS to approve, by
307
regulation, “any other medical condition or its treatment.” Therefore, the definition can expand to provide access to more patients
based on need over time.
Another potential drawback of the Act is its failure to permit patients to cultivate their own marijuana. The NJCMA allows patients to
308
acquire, possess, or transport marijuana, but they may not grow it.
New Jersey will be the only state with a medical-marijuana law that
309
penalizes patients for growing their own marijuana. While this may
prevent abuse, it is also a potential barrier to access for patients.

302

Ken Wolski, The New Jersey Compassionate Use Medical Marijuana Act., COALITION
MED.
MARIJUANA
N.J.
(July
21,
2009,
11:27
AM),
http://cmmnj.blogspot.com/2009/09/new-jersey-compassionate-use-medical.html.
303
Id.
304
See, e.g., COLO. CONST. art. XVIII, § 14 (LEXIS through 67th Gen. Assembly, 1st
Sess.); ALASKA STAT. § 17.37.070 (LexisNexis, LEXIS through 2010 Reg. Sess.); CAL.
HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011
Supp.); HAW. REV. STAT. § 329-121 (LexisNexis, LEXIS through 2010 Reg. Sess.);
MICH. COMP. LAWS ANN. § 333.26423 (LexisNexis, LEXIS through P.A. 383 of 2010
Leg. Sess.); MONT. CODE ANN. § 50-46-102 (LexisNexis, LEXIS through 2009 Reg. and
Spec. Sess.); NEV. REV. STAT. § 453A.050 (LexisNexis, LEXIS through 2010 Reg. Sess.);
OR. REV. STAT. § 475.302 (LEXIS through 2009 Legis. Sess.); R.I. GEN. LAWS § 21-28.6-3
(LEXIS through Jan. 2010 Legis. Sess.); VT. STAT. ANN. tit. 18, § 4472 (LEXIS through
2010 Sess.); WASH. REV. CODE § 69.51A.010 (LexisNexis, LEXIS through 2010 Reg.
and 2d Spec. Sess.). But see ME. REV. STAT. tit. 22, § 2383-B (LexisNexis, LEXIS
through 2009 2d Reg. Legis. Sess.).
305
See N.J. STAT. ANN. § 24:6I-3 (West 2010).
306
CAL. HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011 Supp.).
307
N.J. STAT. ANN. § 24:6I-3 (West 2010).
308
Id.
309
EDDY, supra note 46, at 18.
FOR
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In California, federal authorities have “raided more than 190
310
medical marijuana locations, mostly dispensaries,” and after California enacted its medical-marijuana law, the United States sued to
enjoin a non-profit California dispensary from distributing the drug
311
on the grounds that the cooperative’s activities violated the CSA. In
United States v. Oakland Cannabis Buyer’s Coop., the Supreme Court
held that no medical-necessity defense exception to the CSA’s prohi312
Thus,
bition on marijuana manufacturing and distribution exists.
federal authorities could shut down any New Jersey alternative treatment center and prevent qualified patients from obtaining marijuana. In contrast to New Jersey, California allows patients to cultivate
313
their own marijuana. Therefore, the closure of dispensaries in California would be less problematic for patients because they could
simply grow their own marijuana.
The NJCMA also requires a patient’s certifying physician to be
314
licensed to practice medicine in New Jersey.
This requirement forecloses a patient’s ability to seek the care of a specialist in a neighboring state. Patients should be free to seek the best care possible.
Vermont, for example, allows patients to seek the care of physicians
licensed in other states, including New Hampshire, Massachusetts,
315
and New York.
New Jersey should similarly respect patient choice
and allow patients to seek the treatment of out-of-state doctors.
The NJCMA should also include two additional provisions. First,
the Legislature should consider giving registry identification cards
from other states full force and effect, as Montana, Rhode Island, and
316
Michigan have done.
Compassion dictates that no patient using
marijuana should face criminal penalties in New Jersey if the patient
received proper authorization to use marijuana in another state and
is in possession of valid documentation. Second, the law should not
interfere with a patient’s parental or custodial rights; unless the parent presents a danger to the child, using medical marijuana in accor310

MARIJUANA POLICY PROJECT, supra note 10, at app. F-17.
United States v. Oakland Cannabis Buyers’ Coop., 532 U.S. 483, 486–87
(2001).
312
Id.
313
CAL. HEALTH & SAFETY CODE § 11362.5 (Deering, LEXIS through 2010 legislation and 2011 Supp.).
314
N.J. STAT. ANN. § 24:6I-3 (West 2010).
315
VT. STAT. ANN. tit. 18, § 4472 (LEXIS through 2010 Sess.).
316
MICH. COMP. LAWS ANN. §§ 333.26423–.26424 (LexisNexis, LEXIS through P.A.
383 of 2010 Leg. Sess.); MONT. CODE ANN. § 50-46-201 (LexisNexis, LEXIS through
2009 Reg. and Spec. Sess.); R.I. GEN. LAWS ANN. § 21-28.6-4 (LEXIS through Jan. 2010
Legis. Sess.).
311
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dance with the Act should not affect the parent-child relationship.
Thus, the Act should include the following provision, modeled after
Michigan’s law: “A person shall not be denied custody or visitation of
a minor for acting in accordance with this act, unless the person’s
behavior is such that it creates an unreasonable danger to the minor
317
that can be clearly articulated and substantiated.”
We must not
force individuals suffering from debilitating illnesses to choose between relief and their children.
Finally, the NJCMA does not expressly deal with a number of
important issues, which the regulations promulgated by the DHSS
should address. The Act is silent as to how and from what sources alternative treatment centers would obtain marijuana or marijuana
seeds or seedlings and where the centers’ marijuana would be grown.
It also places no limits on where alternative treatment centers may be
located. Whether the DHSS will impose any zoning limits, such as a
requirement that centers be located at a specified minimum distance
from residential areas or schools, remains to be seen. The NJCMA
also does not explicitly require the DHSS to establish methods for
testing and guaranteeing the quality and safety of marijuana sold at
alternative treatment centers. To ensure that patients have access to
unadulterated, good-quality marijuana, this issue must be addressed
by the DHSS. With respect to cost, the Act only specifies that a center
may charge “for the reasonable costs associated with the production
318
and distribution of marijuana.”
Every two years, the DHSS must
319
evaluate whether centers are charging “excessive prices.”
The
DHSS should prevent costs from serving as a barrier to patient access.
During the drafting process, New Jersey lawmakers expressed
their intention to make the law restrictive enough so that only pa320
tients in serious need could obtain marijuana. They did not want to
321
But at the opposite end of the specencourage illegal drug use.
trum, the law should not be so restrictive that it fails to serve the purpose for which it was intended—to provide medical marijuana to patients in need. As drafted, the NJCMA generally provides the
necessary balance. The aforementioned proposed amendments

317
See MICH. COMP. LAWS ANN. § 333.26424 (LexisNexis, LEXIS through P.A. 383
of 2010 Leg. Sess.).
318
N.J. STAT. ANN. § 24:6I-7(h) (West 2010).
319
Id. § 24:6I-14(c).
320
See Chris Megarian & Susan K. Livio, Making Sure Medical Marijuana Can Be
Used, but Not Abused, STAR LEDGER, June 7, 2009, at 17.
321
Id.
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would also strengthen the protections provided by the Act and help
prevent abuse of the system.
V. CONCLUSION
The legalization of medical marijuana will provide New Jersey
citizens with legal access to a drug that is safe and effective in soothing the symptoms of debilitating medical conditions. For a subset of
patients, botanical marijuana may be the only option for relief. Because marijuana remains a Schedule I controlled substance under
federal law, New Jersey must act to ensure that patients with debilitating conditions avoid prosecution for using marijuana medicinally.
The extensive state regulation, the prohibition of marijuana cultivation, and the limited definition of debilitating illness make New Jersey’s law the most restrictive in the nation. But in addition to preventing abuse and diversion, the NJCMA will provide access to the
drug to patients with the greatest need. Compassion, reason, and
medical evidence require that we distinguish between the medical
and recreational use of marijuana under the law. As of January 18,
2010, this distinction now exists in New Jersey.

